,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,11110984,2803,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,357,2,1,,11110985,2803,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
2,410,1,5,,11110984,2803,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
3,410,1,5,,11110985,2803,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
4,410,1,5,,11113648,2803,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
5,411,2,1,,11110984,2803,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
6,411,2,1,,11110985,2803,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
7,411,2,1,,11113648,2803,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
8,444,1,1,,11110984,2803,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
9,444,1,1,,11110985,2803,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
10,445,3,1,,11110984,2803,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
11,445,3,1,,11110985,2803,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
12,445,3,1,,11113648,2803,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
13,446,1,1,,11110984,2803,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
14,446,1,1,,11110985,2803,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
15,447,1,1,,11110984,2803,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
16,447,1,1,,11110985,2803,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
17,447,1,1,,11113648,2803,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
18,448,1,2,,11110984,2803,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
19,448,1,2,,11110985,2803,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
20,448,1,2,,11113648,2803,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
21,450,1,2,,11110984,2803,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
22,450,1,2,,11110985,2803,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
23,450,1,2,,11113648,2803,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
24,451,1,2,,11110984,2803,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
25,451,1,2,,11110985,2803,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
26,451,1,2,,11113648,2803,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
27,526,1,1,,11110984,2803,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
28,526,1,1,,11110985,2803,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
29,526,1,1,,11113648,2803,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
30,530,1,1,,11110984,2803,Inconclusive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
31,530,1,1,,11110985,2803,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
32,530,1,1,,11113648,2803,Inconclusive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
33,584,1,3,,11110984,2803,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
34,584,1,3,,11110985,2803,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
35,584,1,3,,11113648,2803,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
36,585,1,4,,11110984,2803,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
37,585,1,4,,11110985,2803,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
38,585,1,4,,11113648,2803,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
39,587,1,5,,11110984,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
40,587,1,5,,11110985,2803,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
41,588,1,4,,11110984,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
42,588,1,4,,11110985,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
43,589,1,3,,11110984,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
44,589,1,3,,11110985,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
45,590,1,3,,11110984,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
46,590,1,3,,11110985,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
47,591,1,4,,11110984,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
48,591,1,4,,11110985,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
49,592,1,6,,11110984,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
50,592,1,6,,11110985,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
51,593,1,4,,11110984,2803,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
52,593,1,4,,11110985,2803,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
53,594,1,4,,11110984,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
54,594,1,4,,11110985,2803,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
55,595,1,3,,11110984,2803,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
56,595,1,3,,11110985,2803,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
57,595,1,3,,11113648,2803,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
58,596,1,2,,11110984,2803,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
59,596,1,2,,11110985,2803,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
60,596,1,2,,11113648,2803,Inconclusive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
61,597,1,3,,11110984,2803,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
62,597,1,3,,11110985,2803,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
63,597,1,3,,11113648,2803,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
64,603,1,2,,11110984,2803,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
65,603,1,2,,11110985,2803,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
66,603,1,2,,11113648,2803,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
67,605,1,2,,11110984,2803,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
68,605,1,2,,11110985,2803,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
69,605,1,2,,11113648,2803,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
70,607,1,3,,11110984,2803,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
71,607,1,3,,11110985,2803,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
72,607,1,3,,11113648,2803,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
73,662,1,1,,11110984,2803,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
74,662,1,1,,11110985,2803,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
75,662,1,1,,11113648,2803,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
76,875,1,2,,11110984,2803,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
77,875,1,2,,11110985,2803,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
78,875,1,2,,11113648,2803,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
79,879,1,2,,11110984,2803,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
80,879,1,2,,11110984,2803,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
81,880,2,1,,11110985,2803,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
82,880,2,1,,11110985,2803,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
83,880,2,1,,11113648,2803,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
84,880,2,1,,11113648,2803,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
85,880,2,1,,26751841,2803,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
86,880,2,1,,26751841,2803,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
87,880,2,1,,26751842,2803,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
88,880,2,1,,26751842,2803,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
89,881,2,2,,11110984,2803,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
90,881,2,2,,11110985,2803,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
91,881,2,2,,11113648,2803,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
92,883,1,3,,11110984,2803,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
93,883,1,3,,11110985,2803,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
94,883,1,3,,11113648,2803,Active,13699818.0,1559.0,7.9433,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
95,884,1,2,,11110984,2803,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
96,884,1,2,,11110985,2803,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
97,884,1,2,,11113648,2803,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
98,885,1,2,,11110984,2803,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
99,885,1,2,,11110985,2803,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
100,885,1,2,,11113648,2803,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
101,886,1,2,,11110984,2803,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
102,886,1,2,,11110984,2803,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
103,886,1,2,,11110985,2803,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
104,886,1,2,,11110985,2803,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
105,886,1,2,,11113648,2803,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
106,886,1,2,,11113648,2803,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
107,887,1,2,,11110984,2803,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
108,887,1,2,,11110985,2803,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
109,887,1,2,,11113648,2803,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
110,889,1,3,,11110984,2803,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
111,889,1,3,,11110985,2803,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
112,889,1,3,,11113648,2803,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
113,891,1,2,,11110984,2803,Inconclusive,40805836.0,1565.0,39.8107,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
114,891,1,2,,11110985,2803,Inconclusive,40805836.0,1565.0,7.9433,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
115,891,1,2,,11113648,2803,Active,40805836.0,1565.0,10.0,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
116,892,1,2,,11110984,2803,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
117,892,1,2,,11110985,2803,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
118,892,1,2,,11113648,2803,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
119,893,1,2,,11110984,2803,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
120,893,1,2,,11110984,2803,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
121,893,1,2,,11110985,2803,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
122,893,1,2,,11110985,2803,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
123,893,1,2,,11113648,2803,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
124,893,1,2,,11113648,2803,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
125,894,2,1,,11110985,2803,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
126,894,2,1,,11113648,2803,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
127,895,1,2,,11110984,2803,Inactive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
128,899,1,2,,11110984,2803,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
129,899,1,2,,11110985,2803,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
130,899,1,2,,11113648,2803,Active,4503219.0,1557.0,5.0119,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
131,900,1,3,,11110984,2803,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
132,900,1,3,,11110985,2803,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
133,900,1,3,,11113648,2803,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
134,901,1,2,,11110984,2803,Inconclusive,44888968.0,83523.0,31.6228,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
135,901,1,2,,11110985,2803,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
136,901,1,2,,11113648,2803,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
137,902,1,2,,11110984,2803,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
138,902,1,2,,11110985,2803,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
139,902,1,2,,11113648,2803,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
140,912,1,2,,11110984,2803,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
141,912,1,2,,11110985,2803,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
142,912,1,2,,11113648,2803,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
143,914,1,3,,11110984,2803,Inconclusive,32879895.0,3091.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
144,914,1,3,,11110985,2803,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
145,915,1,3,,11110984,2803,Inconclusive,32879895.0,3091.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
146,915,1,3,,11110985,2803,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
147,917,1,3,,11110984,2803,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
148,918,1,3,,11110984,2803,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
149,923,1,2,,11110984,2803,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
150,923,1,2,,11110985,2803,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
151,923,1,2,,11113648,2803,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
152,924,1,2,,11110984,2803,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
153,924,1,2,,11110985,2803,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
154,924,1,2,,11113648,2803,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
155,925,1,2,,11110984,2803,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
156,925,1,2,,11110985,2803,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
157,926,1,2,,11110984,2803,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
158,926,1,2,,11110985,2803,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
159,926,1,2,,11113648,2803,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
160,927,1,3,,11110984,2803,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
161,927,1,3,,11110985,2803,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
162,928,1,2,,11110984,2803,Inactive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
163,938,1,2,,11110984,2803,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
164,938,1,2,,11110985,2803,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
165,938,1,2,,11113648,2803,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
166,943,1,2,,11110984,2803,Inconclusive,18249941.0,25229.0,25.1189,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
167,944,1,2,,11110984,2803,Inconclusive,18249941.0,25229.0,19.9526,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
168,945,1,4,,11110984,2803,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
169,954,1,2,,11110984,2803,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
170,957,1,2,,11110984,2803,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
171,958,1,2,,11110984,2803,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
172,959,1,4,,11110984,2803,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
173,992,1,3,,11110984,2803,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
174,995,1,2,,11110984,2803,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
175,995,1,2,,11110985,2803,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
176,995,1,2,,11113648,2803,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
177,997,1,2,,11110984,2803,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
178,998,1,2,,11110984,2803,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
179,1030,2,1,,11110985,2803,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
180,1030,2,1,,11113648,2803,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
181,1030,2,1,,26751841,2803,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
182,1030,2,1,,26751842,2803,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
183,1195,1,2,,48415806,2803,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
184,1332,1,1,,49699311,2803,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
185,1379,1,2,,11110985,2803,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
186,1379,1,2,,11113648,2803,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
187,1452,1,1,,11110984,2803,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
188,1452,1,1,,11110985,2803,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
189,1452,1,1,,11113648,2803,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
190,1454,1,1,,11110985,2803,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
191,1454,1,1,,11113648,2803,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
192,1457,1,1,,11110985,2803,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
193,1457,1,1,,11113648,2803,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
194,1457,1,1,,26751841,2803,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
195,1457,1,1,,26751842,2803,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
196,1458,1,1,,11110985,2803,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
197,1458,1,1,,26751841,2803,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
198,1458,1,1,,26751842,2803,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
199,1460,1,3,,11113648,2803,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
200,1460,1,3,,26751841,2803,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
201,1460,1,3,,26751842,2803,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
202,1463,1,1,,11113648,2803,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
203,1463,1,1,,26751841,2803,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
204,1463,1,1,,26751842,2803,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
205,1467,1,3,,11110985,2803,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
206,1467,1,3,,11113648,2803,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
207,1468,1,1,,11113648,2803,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
208,1468,1,1,,26751841,2803,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
209,1468,1,1,,26751842,2803,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
210,1469,1,1,,11110985,2803,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
211,1469,1,1,,11113648,2803,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
212,1469,1,1,,26751841,2803,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
213,1469,1,1,,26751842,2803,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
214,1471,2,1,,11110984,2803,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
215,1471,2,1,,11110985,2803,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
216,1471,2,1,,11113648,2803,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
217,1471,2,1,,26751841,2803,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
218,1471,2,1,,26751842,2803,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
219,1476,2,1,,11110985,2803,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
220,1476,2,1,,11113648,2803,Inconclusive,281307097.0,,39.8107,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
221,1477,1,1,,11110985,2803,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
222,1477,1,1,,11113648,2803,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
223,1477,1,1,,26751841,2803,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
224,1477,1,1,,26751842,2803,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
225,1478,2,1,,11110985,2803,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
226,1478,2,1,,11113648,2803,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
227,1479,1,2,,11110985,2803,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
228,1479,1,2,,11113648,2803,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
229,1479,1,2,,26751841,2803,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
230,1479,1,2,,26751842,2803,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
231,1487,1,1,,11110985,2803,Inconclusive,27436948.0,4000.0,0.2818,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
232,1487,1,1,,26751841,2803,Inconclusive,27436948.0,4000.0,35.4813,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
233,1490,2,1,,11110985,2803,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
234,1490,2,1,,11113648,2803,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
235,1490,2,1,,26751841,2803,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
236,1490,2,1,,26751842,2803,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
237,1519,1,3,,11110985,2803,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
238,1519,1,3,,11113648,2803,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
239,1688,1,1,,26751841,2803,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
240,1766,1,1,,11110985,2803,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
241,1766,1,1,,11110985,2803,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
242,1766,1,1,,11113648,2803,Inconclusive,18860839.0,4221.0,35.4813,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
243,1766,1,1,,11113648,2803,Inconclusive,56550039.0,4297.0,35.4813,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
244,1766,1,1,,26751841,2803,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
245,1766,1,1,,26751841,2803,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
246,1768,1,1,,11110985,2803,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
247,1768,1,1,,11110985,2803,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
248,1768,1,1,,11113648,2803,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
249,1768,1,1,,11113648,2803,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
250,1768,1,1,,26751841,2803,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
251,1768,1,1,,26751841,2803,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
252,1851,1,2,,11110984,2803,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
253,1851,1,2,,11110985,2803,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
254,1851,1,2,,11113648,2803,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
255,1851,1,2,1.0,11110984,2803,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
256,1851,1,2,1.0,11110985,2803,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
257,1851,1,2,1.0,11113648,2803,Active,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
258,1851,1,2,2.0,11110984,2803,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
259,1851,1,2,2.0,11110985,2803,Inconclusive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
260,1851,1,2,2.0,11113648,2803,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
261,1851,1,2,3.0,11110984,2803,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
262,1851,1,2,3.0,11110985,2803,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
263,1851,1,2,3.0,11113648,2803,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
264,1851,1,2,4.0,11110984,2803,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
265,1851,1,2,4.0,11110985,2803,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
266,1851,1,2,4.0,11113648,2803,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
267,1851,1,2,5.0,11110984,2803,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
268,1851,1,2,5.0,11110985,2803,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
269,1851,1,2,5.0,11113648,2803,Active,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
270,1865,1,1,,11110985,2803,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
271,1865,1,1,,11113648,2803,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
272,1865,1,1,,26751841,2803,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
273,1865,1,1,,26751842,2803,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
274,1948,1,1,,11110985,2803,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
275,1948,1,1,,11113648,2803,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
276,2062,1,2,,85209030,2803,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
277,2101,1,1,,11110985,2803,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
278,2101,1,1,,11113648,2803,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
279,2101,1,1,,26751841,2803,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
280,2101,1,1,,26751842,2803,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
281,2107,1,1,,11110985,2803,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
282,2107,1,1,,11113648,2803,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
283,2107,1,1,,26751841,2803,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
284,2107,1,1,,26751842,2803,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
285,2112,1,1,,11110985,2803,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
286,2112,1,1,,11113648,2803,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
287,2112,1,1,,26751841,2803,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
288,2112,1,1,,26751842,2803,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
289,2147,1,1,,11110985,2803,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
290,2147,1,1,,11113648,2803,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
291,2240,1,1,,85787756,2803,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
292,2240,1,1,,85788378,2803,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
293,2241,1,1,,85787756,2803,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
294,2241,1,1,,85788378,2803,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
295,2275,1,1,,85787756,2803,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
296,2275,1,1,,85788378,2803,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
297,2313,1,1,,85787756,2803,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
298,2313,1,1,,85788378,2803,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
299,2316,1,1,,85787756,2803,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
300,2322,1,1,,85787756,2803,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
301,2322,1,1,,85788378,2803,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
302,2330,1,1,,85787756,2803,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
303,2330,1,1,,85788378,2803,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
304,2451,1,2,,11110985,2803,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
305,2451,1,2,,11113648,2803,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
306,2472,1,2,,11110985,2803,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
307,2472,1,2,,11113648,2803,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
308,2517,2,1,,11110985,2803,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
309,2517,2,1,,11113648,2803,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
310,2517,2,1,,26751841,2803,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
311,2517,2,1,,26751842,2803,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
312,2528,1,2,,11110985,2803,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
313,2528,1,2,,11113648,2803,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
314,2528,1,2,,26751841,2803,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
315,2546,1,1,,11110985,2803,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
316,2546,1,1,,11113648,2803,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
317,2546,1,1,,26751841,2803,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
318,2549,1,1,,11110985,2803,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
319,2549,1,1,,11113648,2803,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
320,2549,1,1,,26751841,2803,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
321,2549,1,1,,26751842,2803,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
322,2551,1,1,,11110985,2803,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
323,2551,1,1,,11113648,2803,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
324,2551,1,1,,26751841,2803,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
325,2660,1,1,,90341662,2803,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
326,2666,1,1,,90341662,2803,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
327,2667,1,1,,90341662,2803,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
328,2668,1,1,,90341662,2803,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
329,7783,3,4,,103189246,2803,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
330,8002,5,2,,103189246,2803,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
331,15974,3,3,,103189246,2803,Unspecified,,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Other,6502601.0,
332,15976,3,4,,103189246,2803,Unspecified,,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Other,6502601.0,
333,15983,3,3,,103189246,2803,Unspecified,,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Other,6502601.0,
334,16331,3,4,,103189246,2803,Unspecified,,,,,Delta logPoct-cyc,Other,2894467.0,
335,19258,3,3,,103189246,2803,Unspecified,,,,,Logarithm of partition coefficient of the neutral form of compound given for chloroform/water solvent system,Other,2894467.0,
336,19260,3,3,,103189246,2803,Unspecified,,,,,Logarithm of partition coefficient of the neutral form of compound given for octanol/water solvent system,Other,2894467.0,
337,19424,3,4,,103189246,2803,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
338,22293,4,4,,103189246,2803,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
339,23238,3,3,,103189246,2803,Unspecified,,,,,Partition coefficient (logP),Other,7143348.0,
340,23716,3,4,,103189246,2803,Unspecified,,,,,Partition coefficient (logD7.4),Other,6264080.0,
341,24217,3,5,,103189246,2803,Unspecified,,,,,Apparent partion coefficient of compound was evaluated in octanol/buffer at pH of 7.4 at 37 degree Centigrade,Other,6142954.0,
342,25092,4,3,,103189246,2803,Unspecified,,,,,Ionization constant (pKa),Other,2066976.0,
343,26304,4,4,,103189246,2803,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
344,26362,4,3,,103189246,2803,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
345,26594,3,3,,103189246,2803,Unspecified,,,,,pKa values were observed,Other,8411009.0,
346,28233,3,3,,103189246,2803,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
347,28235,3,3,,103189246,2803,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
348,28236,3,3,,103189246,2803,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
349,29337,3,3,,103189246,2803,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
350,29359,3,3,,103189246,2803,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
351,29423,3,4,,103189246,2803,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
352,29811,4,3,,103189246,2803,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
353,29925,5,2,,103189246,2803,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
354,32094,9,1,,103189246,2803,Inconclusive,,,,IC50,Inhibitory activity against acetylcholinesterase in rat striatal preparation,Confirmatory,8558529.0,
355,33250,3,7,,103189246,2803,Unspecified,,,,,Central hypotensive activity in anesthetized normotensive rats.,Other,6264080.0,
356,33252,3,7,,103189246,2803,Unspecified,,,,,Peripheral hypertensive activity in pithed normotensive rats.,Other,6264080.0,
357,35184,4,1,,103189246,2803,Active,,,0.97724,Ki,Binding affinity towards human Alpha-1C adrenergic receptor by the displacement of [3H]prazosin,Confirmatory,,
358,35187,7,5,,103189246,2803,Active,231461.0,25083.0,0.0057,Ki,Displacement of [3H]clonidine from Alpha-2 adrenergic receptor of rat brain membranes,Confirmatory,6296387.0,
359,35187,7,5,,103189246,2803,Active,231464.0,24175.0,0.0057,Ki,Displacement of [3H]clonidine from Alpha-2 adrenergic receptor of rat brain membranes,Confirmatory,6296387.0,
360,35187,7,5,,103189246,2803,Active,47117345.0,24174.0,0.0057,Ki,Displacement of [3H]clonidine from Alpha-2 adrenergic receptor of rat brain membranes,Confirmatory,6296387.0,
361,35192,7,1,,103189246,2803,Active,,,0.03,Ki,Binding affinity towards alpha-2 adrenergic receptor in rat using [3H]rauwolscine as radioligand,Confirmatory,2864446.0,
362,35207,4,1,,103189246,2803,Unspecified,,,,,In vitro agonist activity against alpha-2 adrenoceptor in rat vas deferens,Other,2567783.0,
363,35210,3,6,,103189246,2803,Active,,,,,In vitro antagonistic activity against alpha-2 adrenoceptor in rat vas deferens; Ag means compound was agonist.,Other,2567783.0,
364,35271,7,1,,103189246,2803,Active,,,0.5276,Ki,Compound was tested for the inhibition of [3H]prazosin binding Alpha-1 adrenergic receptor of crude rat brain membrane.,Confirmatory,6123600.0,
365,35412,7,2,,103189246,2803,Active,,,0.31,Ki,In vitro binding affinity was measured as the inhibition of [3H]WB-4101 binding to alpha-1 adrenergic receptor of rat cortical membranes,Confirmatory,3016265.0,
366,35422,7,5,,103189246,2803,Active,543734.0,24173.0,0.11599999999999999,Ki,Tested for Binding affinity towards alpha-1 adrenergic receptor,Confirmatory,10715142.0,
367,35422,7,5,,103189246,2803,Active,1168244.0,29413.0,0.11599999999999999,Ki,Tested for Binding affinity towards alpha-1 adrenergic receptor,Confirmatory,10715142.0,
368,35422,7,5,,103189246,2803,Active,1168247.0,29412.0,0.11599999999999999,Ki,Tested for Binding affinity towards alpha-1 adrenergic receptor,Confirmatory,10715142.0,
369,35430,7,1,,103189246,2803,Active,,,0.52,Ki,Binding affinity against alpha-1 adrenergic receptor in rat using [3H]prazosin as radioligand,Confirmatory,2864446.0,
370,35437,7,2,,103189246,2803,Active,,,0.11599999999999999,Ki,"in vitro alpha-1 adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand",Confirmatory,10753480.0,
371,35568,4,3,,103189246,2803,Unspecified,543734.0,24173.0,,,In vitro agonist activity against alpha-1 adrenoceptor in rat anococcygeus,Other,2567783.0,
372,35568,4,3,,103189246,2803,Unspecified,1168244.0,29413.0,,,In vitro agonist activity against alpha-1 adrenoceptor in rat anococcygeus,Other,2567783.0,
373,35568,4,3,,103189246,2803,Unspecified,1168247.0,29412.0,,,In vitro agonist activity against alpha-1 adrenoceptor in rat anococcygeus,Other,2567783.0,
374,35572,3,11,,103189246,2803,Active,543734.0,24173.0,,,In vitro antagonistic activity against alpha1 adrenoceptor in rat anococcygeus; Ag means compound was agonist.,Other,2567783.0,
375,35572,3,11,,103189246,2803,Active,1168244.0,29413.0,,,In vitro antagonistic activity against alpha1 adrenoceptor in rat anococcygeus; Ag means compound was agonist.,Other,2567783.0,
376,35572,3,11,,103189246,2803,Active,1168247.0,29412.0,,,In vitro antagonistic activity against alpha1 adrenoceptor in rat anococcygeus; Ag means compound was agonist.,Other,2567783.0,
377,35772,3,7,,103189246,2803,Unspecified,,,,,Compound was evaluated for hypotensive activity mediated by Alpha-2 adrenergic receptor; no data,Other,12723959.0,
378,35806,3,7,,103189246,2803,Unspecified,,,,,Presynaptic Alpha-2 adrenergic receptor agonist activity in isolated tissue of rat or mouse vas deferens,Other,6133953.0,
379,35898,9,2,,103189246,2803,Active,,,0.002,IC50,Concentration necessary to achieve half maximal inhibition of [3H]clonidine binding to Alpha-2 adrenergic receptor at 1 uM,Confirmatory,2537429.0,
380,35934,8,5,,103189246,2803,Active,1351829.0,150.0,0.0038,Ki,Binding affinity for human Alpha-2A adrenergic receptor,Confirmatory,8632424.0,
381,35946,7,1,,103189246,2803,Active,,,0.0038,Ki,Compound was tested in vitro for binding affinity against Alpha-2A adrenergic receptor from cloned human C-10 receptor transfected into Chinese hamster ovary (CHO) cells,Confirmatory,8784451.0,
382,35950,8,5,,103189246,2803,Active,1351829.0,150.0,0.853,Ki,Binding affinity towards Alpha-2A adrenergic receptor,Confirmatory,10715142.0,
383,35959,4,1,,103189246,2803,Active,,,0.00813,EC50,Agonistic activity towards human Alpha-2A adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate,Confirmatory,,
384,36075,4,1,,103189246,2803,Active,,,0.007940000000000001,Ki,Binding affinity towards human Alpha-2A adrenergic receptor by the displacement of [3H]rauwolscine,Confirmatory,,
385,36094,7,2,,103189246,2803,Active,,,0.853,Ki,"in vitro alpha-2A adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand",Confirmatory,10753480.0,
386,36104,7,2,,103189246,2803,Active,,,0.51,Ki,Compound was tested for binding affinity based on dissociation constant of Alpha-1 adrenergic receptor,Confirmatory,8784451.0,
387,36128,7,5,,103189246,2803,Active,1168243.0,146.0,0.51,Ki,Binding affinity for human brain Alpha-1 adrenergic receptor,Confirmatory,8632424.0,
388,36128,7,5,,103189246,2803,Active,1168246.0,148.0,0.51,Ki,Binding affinity for human brain Alpha-1 adrenergic receptor,Confirmatory,8632424.0,
389,36128,7,5,,103189246,2803,Active,116241241.0,147.0,0.51,Ki,Binding affinity for human brain Alpha-1 adrenergic receptor,Confirmatory,8632424.0,
390,36159,8,2,,103189246,2803,Active,,,0.25704,Kd,The compound was tested for alpha-adrenergic activity against Alpha-1 adrenergic receptor from rat aorta.,Confirmatory,1956038.0,
391,36161,3,7,,103189246,2803,Unspecified,,,,,The compound was tested for alpha-adrenergic activity against Alpha-1 adrenergic receptor from rat aorta.,Other,1956038.0,
392,36178,4,7,,103189246,2803,Unspecified,,,,,The compound was tested for alpha-adrenergic activity against alpha-2 adrenergic receptor from guinea pig vas deferens.,Other,1956038.0,
393,36188,9,2,,103189246,2803,Active,,,0.021,IC50,Inhibition of [3H]p-aminoclonidine (PAC) binding to alpha-2 adrenergic receptor of purified human platelet plasma membranes,Confirmatory,3037080.0,
394,36232,4,1,,103189246,2803,Active,,,0.16596,EC50,Agonistic activity towards human Alpha-2B adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate,Confirmatory,,
395,36241,4,1,,103189246,2803,Active,,,0.00617,Ki,Binding affinity towards human Alpha-2B adrenergic receptor by the displacement of [3H]rauwolscine,Confirmatory,,
396,36251,8,5,,103189246,2803,Active,47117345.0,24174.0,0.0083,Ki,Binding affinity for rat Alpha-2B adrenergic receptor,Confirmatory,8632424.0,
397,36261,4,6,,103189246,2803,Active,,,0.29,EC50,Compound was tested for concentration that produced 50% contractile relative response to maximum response to norepinephrine for Alpha-1 adrenergic receptor,Confirmatory,8784451.0,
398,36357,3,10,,103189246,2803,Active,231460.0,11551.0,,,Inhibition of alpha-2 adrenergic receptor,Other,6143826.0,
399,36357,3,10,,103189246,2803,Active,231463.0,11553.0,,,Inhibition of alpha-2 adrenergic receptor,Other,6143826.0,
400,36357,3,10,,103189246,2803,Active,68067981.0,11552.0,,,Inhibition of alpha-2 adrenergic receptor,Other,6143826.0,
401,36373,7,1,,103189246,2803,Active,,,0.0083,Ki,Compound was tested in vitro for binding affinity against Alpha-2B adrenergic receptor from cloned rat RNG receptor transfected into Chinese hamster ovary (CHO) cells,Confirmatory,8784451.0,
402,36375,7,2,,103189246,2803,Active,,,0.16,Ki,"in vitro alpha-2B adrenergic receptor binding assay from rats, using RX 821002 as the displaceable ligand",Confirmatory,10753480.0,
403,36396,8,5,,103189246,2803,Active,20141211.0,152.0,0.03,Ki,Binding affinity for human Alpha-2C adrenergic receptor,Confirmatory,8632424.0,
404,36404,7,1,,103189246,2803,Active,,,0.03,Ki,Compound was tested in vitro for binding affinity against Alpha-2C adrenergic receptor from cloned human C-2 receptor transfected into Chinese hamster ovary (CHO) cells,Confirmatory,8784451.0,
405,36407,8,5,,103189246,2803,Active,20141211.0,152.0,0.16,Ki,Binding affinity towards alpha-2C adrenergic receptor,Confirmatory,10715142.0,
406,36493,3,10,,103189246,2803,Unspecified,231460.0,11551.0,,,Presynaptic alpha-2 adrenergic receptor agonist activity in isolated mouse vas deferens,Other,6143826.0,
407,36493,3,10,,103189246,2803,Unspecified,231463.0,11553.0,,,Presynaptic alpha-2 adrenergic receptor agonist activity in isolated mouse vas deferens,Other,6143826.0,
408,36493,3,10,,103189246,2803,Unspecified,68067981.0,11552.0,,,Presynaptic alpha-2 adrenergic receptor agonist activity in isolated mouse vas deferens,Other,6143826.0,
409,36512,4,7,,103189246,2803,Active,,,0.0044,EC50,Compound was tested for concentration that produced 50% contractile relative response to maximum response to norepinephrine for Alpha-2 adrenergic receptor,Confirmatory,8784451.0,
410,36526,4,1,,103189246,2803,Active,,,0.05495,EC50,Agonistic activity towards human Alpha-2C adrenergic receptor was measured as ability to inhibit forskolin-stimulated synthesis of cyclic adenosine monophosphate,Confirmatory,,
411,36536,4,1,,103189246,2803,Active,,,0.056229999999999995,Ki,Binding affinity towards human Alpha-2C adrenergic receptor by the displacement of [3H]rauwolscine,Confirmatory,,
412,36551,8,5,,103189246,2803,Active,231461.0,25083.0,0.00039,Ki,Binding affinity towards alpha-2D adrenergic receptor,Confirmatory,10715142.0,
413,36555,8,5,,103189246,2803,Active,231461.0,25083.0,0.00039,Ki,In vitro rat alpha-2D adrenergic receptor binding using p-aminoclonidine,Confirmatory,10753480.0,
414,36715,9,1,,103189246,2803,Active,,,1.2,IC50,Binding affinity against alpha-1 adrenergic receptor is the ability to inhibit the specific [3H]prazosin binding (0.4 nM) to rat isolated brain membranes by 50% was reported.,Confirmatory,6142954.0,
415,36752,4,1,,103189246,2803,Active,,,0.51286,Ki,Binding affinity towards human Alpha-1A adrenergic receptor by the displacement of [3H]prazosin,Confirmatory,,
416,36783,9,2,,103189246,2803,Active,,,0.0031,IC50,50% inhibition of specific [3H]clonidine binding (0.4 nM) to Alpha-2 adrenergic receptors in rat isolated brain membranes,Confirmatory,6142954.0,
417,36935,4,6,,103189246,2803,Active,,,0.0039,IC50,The compound was evaluated for the alpha-2 adrenergic receptor antagonistic activity in rat vas deferens vs clonidine,Confirmatory,2887657.0,
418,37078,7,2,,103189246,2803,Active,,,0.0018,Ki,Binding affinity against alpha-2 adrenergic receptor was determined by the displacement of [3H]clonidine from rat brain cortical membranes,Confirmatory,2887657.0,
419,37082,7,1,,103189246,2803,Active,,,0.03,Ki,Binding affinity for alpha-2 adrenergic receptor in rat cortex using [3H]rauwolscine.,Confirmatory,2884313.0,
420,37303,7,1,,103189246,2803,Active,,,0.52,Ki,Binding affinity for alpha-1 adrenergic receptor in rat liver using [3H]prazosin.,Confirmatory,2884313.0,
421,37363,7,1,,103189246,2803,Active,,,0.0017,Ki,Compound was tested for the inhibition of [3H]clonidine binding Alpha-2 adrenergic receptor of crude rat brain membrane,Confirmatory,6123600.0,
422,37381,7,2,,103189246,2803,Active,,,0.0015,Ki,In vitro binding affinity was measured as the inhibition of [3H]clonidine binding to alpha-2 adrenergic receptor of rat cortical membranes,Confirmatory,3016265.0,
423,37477,4,1,,103189246,2803,Unspecified,,,416869000000.0,Ki,Binding affinity towards human Alpha-1B adrenergic receptor by the displacement of [3H]prazosin,Confirmatory,,
424,39946,9,2,,103189246,2803,Unspecified,,,63.0957,Kd,The compound was tested for beta-adrenergic activity against Beta-1 adrenergic receptor from guinea pig left atria,Confirmatory,1956038.0,
425,39947,9,2,,103189246,2803,Active,,,39.8107,Kd,The compound was tested for beta-adrenergic activity against Beta-1 adrenergic receptor from guinea pig right atria,Confirmatory,1956038.0,
426,49601,3,4,,103189246,2803,Unspecified,,,,,Hypotensive activity measured as the 20% decrease in mean arterial blood pressure in anesthetized cat,Other,7143348.0,
427,58629,3,4,,103189246,2803,Unspecified,,,,,Oral dose required to cause 20% fall in blood pressure,Other,7452693.0,
428,58630,3,3,,103189246,2803,Unspecified,,,,,Oral dose required to cause 20% fall in sedation; Range is 0.25-0.50,Other,7452693.0,
429,63016,7,1,,103189246,2803,Unspecified,,,4.0,Ki,In vitro binding affinity to Dopamine receptors of rat striatal membranes by [3H]spiroperidol displacement.,Confirmatory,3016265.0,
430,91481,4,7,,103189246,2803,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
431,111995,3,4,,103189246,2803,Unspecified,,,,,Antagonistic activity against Scopolamine induced behavioral deficits in mice; 0/6,Other,8558529.0,
432,114183,6,2,,103189246,2803,Unspecified,,,,,Effective dose against administration in mice,Other,8558529.0,
433,126323,3,3,,103189246,2803,Unspecified,,,,,Oral dose required to cause 20% fall in sedation; Increase in foot shock rate,Other,7452693.0,
434,128510,9,1,,103189246,2803,Unspecified,,,,,Analgesic activity was determined in mouse writhing test,Other,3411603.0,
435,133238,3,4,,103189246,2803,Unspecified,,,,,"Tested for antinociceptive activity at a screening dose of 30 mg/kg, po in the mouse abdominal irritant test (MAIT) using acetylcholine as irritant.[95% confidence limit]",Other,10715142.0,
436,135326,5,2,,103189246,2803,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
437,139799,3,3,,103189246,2803,Unspecified,,,,,Agonist potency of clonidine in the mouse electrically stimulated vas deferens,Other,2875186.0,
438,141668,8,4,,103189246,2803,Inconclusive,,,,,Inhibition of [3H]quinuclidinyl benzilate (QNB) binding from rat forebrain membranes in the absence of Zn; Not tested,Other,8558529.0,
439,141670,8,4,,103189246,2803,Inconclusive,,,,,Inhibition of [3H]quinuclidinyl benzilate (QNB) binding from rat forebrain membranes in the presence of Zn; Not tested,Other,8558529.0,
440,168899,3,6,,103189246,2803,Unspecified,,,,,Intrinsic activity expressed as ratio of maximum responses to the compound to the maximum response to norepinephrine.,Other,1956038.0,
441,170661,3,4,,103189246,2803,Unspecified,,,,,Tested for the change in diastolic blood pressure administered at 0.108 ug/kg intravenously in anesthetized rats,Other,8411013.0,
442,170825,3,4,,103189246,2803,Unspecified,,,,,Tested for the change in systolic blood pressure administered at 0.108 ug/kg intravenously in anesthetized rats,Other,8411013.0,
443,171641,3,4,,103189246,2803,Unspecified,,,,,Change in diastolic blood pressure after iv administration of 0.108 uM/kg in anesthetized rats,Other,10447956.0,
444,171674,3,4,,103189246,2803,Unspecified,,,,,Change in systolic blood pressure after iv administration of 0.108 uM/kg in anesthetized rats,Other,10447956.0,
445,171843,3,5,,103189246,2803,Unspecified,,,,,Hypotensive activity in the rat as change in blood pressure (mmHg) at 24 hr after of 1 mg/kg oral dose of the compound,Other,3411603.0,
446,171847,3,5,,103189246,2803,Unspecified,,,,,Hypotensive activity in the rat as change in blood pressure (mmHg) at 4 hr after a 50 mg/kg oral dose of the compound,Other,3411603.0,
447,172271,3,4,,103189246,2803,Unspecified,,,,,"Effect on heart rate of spontaneously hypertensive rats, 10 hr after peroral administration of 0.3 mg/kg of compound",Other,7265125.0,
448,172273,3,4,,103189246,2803,Unspecified,,,,,"Effect on heart rate of spontaneously hypertensive rats, 10 hr after peroral administration of 1 mg/kg of compound",Other,7265125.0,
449,172275,3,4,,103189246,2803,Unspecified,,,,,"Effect on heart rate of spontaneously hypertensive rats, 10 hr after peroral administration of 3 mg/kg of compound",Other,7265125.0,
450,172280,3,4,,103189246,2803,Unspecified,,,,,"Effect on heart rate of spontaneously hypertensive rats, 24 hr after peroral administration of 0.3 mg/kg of compound",Other,7265125.0,
451,172281,3,4,,103189246,2803,Unspecified,,,,,"Effect on heart rate of spontaneously hypertensive rats, 24 hr after peroral administration of 1 mg/kg of compound",Other,7265125.0,
452,172283,3,4,,103189246,2803,Unspecified,,,,,"Effect on heart rate of spontaneously hypertensive rats, 24 hr after peroral administration of 3 mg/kg of compound",Other,7265125.0,
453,172285,3,4,,103189246,2803,Unspecified,,,,,"Effect on heart rate of spontaneously hypertensive rats, 2 hr after peroral administration of 0.3 mg/kg of compound",Other,7265125.0,
454,172286,3,4,,103189246,2803,Unspecified,,,,,"Effect on heart rate of spontaneously hypertensive rats, 2 hr after peroral administration of 1 mg/kg of compound",Other,7265125.0,
455,172288,3,4,,103189246,2803,Unspecified,,,,,"Effect on heart rate of spontaneously hypertensive rats, 2 hr after peroral administration of 3 mg/kg of compound",Other,7265125.0,
456,173516,3,4,,103189246,2803,Unspecified,,,,,"Maximum percent decrease in heart rate of spontaneously hypertensive rats, 10 hours after peroral administration of 3 mg/kg of compound",Other,7265125.0,
457,173527,4,4,,103189246,2803,Unspecified,,,,,"Maximum percent decrease in heart rate of spontaneously hypertensive rats, 6 hours after peroral administration of 3 mg/kg of compound",Other,7265125.0,
458,173906,3,4,,103189246,2803,Unspecified,,,,,Hypotensive response (diastolic blood pressure) was determined at 30 minutes for a dose of 0.1 mg/kg administered and 1 mL of corn oil in rat,Other,7154013.0,
459,173907,3,4,,103189246,2803,Unspecified,,,,,Hypotensive response (systolic blood pressure) was determined at 30 minutes for a dose of 0.1 mg/kg administered and 1 mL of corn oil in rat,Other,7154013.0,
460,173920,4,4,,103189246,2803,Unspecified,,,,,Oral dose required to cause 20% fall in blood pressure,Other,7452693.0,
461,173921,4,3,,103189246,2803,Unspecified,,,,,Oral dose required to cause 20% fall in sedation,Other,7452693.0,
462,174075,3,5,,103189246,2803,Unspecified,,,,,"Antihypertensive activity was measured as decrease in systolic blood pressure in spontaneously hypertensive rats at 75 mg/kg, po 5 hours after dosing",Other,1404232.0,
463,174419,3,4,,103189246,2803,Unspecified,,,,,Change in systolic blood pressure after 100 ug/kg oral administration in spontaneous hypertensive rats after 24 hr,Other,7310823.0,
464,174420,3,4,,103189246,2803,Unspecified,,,,,Change in systolic blood pressure after 100 ug/kg oral administration in spontaneous hypertensive rats after 2 hr,Other,7310823.0,
465,174421,3,4,,103189246,2803,Unspecified,,,,,Change in systolic blood pressure after 100 ug/kg oral administration in spontaneous hypertensive rats after 4 hr,Other,7310823.0,
466,174562,3,4,,103189246,2803,Unspecified,,,,,Change in systolic blood pressure after 50 ug/kg oral administration in spontaneous hypertensive rats after 24 hr,Other,7310823.0,
467,174563,3,4,,103189246,2803,Unspecified,,,,,Change in systolic blood pressure after 50 ug/kg oral administration in spontaneous hypertensive rats after 2 hr,Other,7310823.0,
468,174564,3,4,,103189246,2803,Unspecified,,,,,Change in systolic blood pressure after 50 ug/kg oral administration in spontaneous hypertensive rats after 4 hr,Other,7310823.0,
469,174893,3,4,,103189246,2803,Unspecified,,,,,Oral hypotensive activity in spontaneously hypertensive rats by using tail-cuff method measured as change in systolic BP at the dose of 0.25 mg/kg po.,Other,6620309.0,
470,175542,3,3,,103189246,2803,Unspecified,,,,,Effect of compound on hyperreflexia in spinal transected rats at 12.5 ug/Kg,Other,8289185.0,
471,175544,3,3,,103189246,2803,Unspecified,,,,,Effect of compound on hyperreflexia in spinal transected rats at 3.1 ug/Kg,Other,8289185.0,
472,175547,3,3,,103189246,2803,Unspecified,,,,,Effect of compound on hyperreflexia in spinal transected rats at 50 ug/Kg,Other,8289185.0,
473,175549,3,3,,103189246,2803,Unspecified,,,,,Effect of compound on reflux function in spinal transected rats at 12.5 ug/Kg,Other,8289185.0,
474,175551,3,3,,103189246,2803,Unspecified,,,,,Effect of compound on reflux function in spinal transected rats at 3.1 ug/Kg,Other,8289185.0,
475,175554,3,3,,103189246,2803,Unspecified,,,,,Effect of compound on reflux function in spinal transected rats at 50 ug/Kg,Other,8289185.0,
476,179133,3,3,,103189246,2803,Unspecified,,,,,Compound is measured for oral antihypertensive activity in groups of 6-12 deoxy-corticosterone-sodium hypertensive (DOCA-Na) rats at 0.5 mg/kg,Other,7452693.0,
477,180082,6,1,,103189246,2803,Unspecified,,,,,"Antihypertensive activity determined as heart rate in SH rats, was reported at a dose of 100 mg/Kg",Other,6502601.0,
478,180083,6,1,,103189246,2803,Unspecified,,,,,"Antihypertensive activity determined as heart rate in SH rats, was reported at a dose of 25 mg/Kg",Other,6502601.0,
479,180235,6,1,,103189246,2803,Unspecified,,,,,Assessment of antihypertensive activity at 100 mg/kg administered perorally by measuring the heart rate in rats,Other,2918504.0,
480,180829,6,1,,103189246,2803,Unspecified,,,,,Tested for change in heart rate administered at 0.108 uM/kg iv in anesthetized rats,Other,8411013.0,
481,181262,6,2,,103189246,2803,Unspecified,,,,,"tested for antinociceptive activity at a screening dose of 30 mg/kg, po in the rat air-induced abdominal irritant test (RAIT) using acetylcholine as irritant",Other,10715142.0,
482,181769,3,3,,103189246,2803,Unspecified,,,,,Compound is measured for oral antihypertensive activity in groups of 6-12 conscious spontaneously hypertensive rats at 0.5 mg/kg,Other,7452693.0,
483,182611,7,2,,103189246,2803,Unspecified,,,,,Antisecretory activity determined after (sc) administration in rat using rat cholera toxin secretion assay,Other,1967650.0,
484,183611,3,3,,103189246,2803,Unspecified,,,,,First ionization energy by intravenous administration to rats,Other,6105218.0,
485,186204,3,3,,103189246,2803,Unspecified,,,,,Hypotensive activity by intravenous administration to rats,Other,6105218.0,
486,186357,3,4,,103189246,2803,Unspecified,,,,,"Antihypertensive activity in SH rats, and mean arterial blood pressure was reported at a dose of 100 mg/Kg",Other,6502601.0,
487,186358,3,4,,103189246,2803,Unspecified,,,,,"Antihypertensive activity in SH rats, and mean arterial blood pressure was reported at a dose of 25 mg/Kg",Other,6502601.0,
488,186692,3,4,,103189246,2803,Unspecified,,,,,Assessment of antihypertensive activity at 100 mg/kg administered perorally by measuring mean arterial blood pressure (MABP) in rats,Other,2918504.0,
489,192741,3,3,,103189246,2803,Unspecified,,,,,Maximum rate of rise of the left ventricular isovolumetric pressure was measured after iv administration of 0.108 uM/kg in anesthetized rats,Other,10447956.0,
490,192796,3,3,,103189246,2803,Unspecified,,,,,Maximum rate of rise of the left ventricular isovolumetric pressure administered at 0.108 uM/kg iv in anesthetized rats,Other,8411013.0,
491,193681,3,3,,103189246,2803,Unspecified,,,,,Maximum rate of rise of the left ventricular isovolumetric pressure in anesthetized rats by i.v. administration,Other,10576697.0,
492,193687,3,4,,103189246,2803,Unspecified,,,,,Percent change in diastolic blood pressure (mmHg)in anesthetized rats by i.v. administration,Other,10576697.0,
493,193688,3,4,,103189246,2803,Unspecified,,,,,Percent change in heart rate expressed in beats / min in anesthetized rats by i.v. administration,Other,10576697.0,
494,193699,3,4,,103189246,2803,Unspecified,,,,,Percent change in systolic blood pressure (mmHg)in anesthetized rats by i.v. administration,Other,10576697.0,
495,193760,6,1,,103189246,2803,Unspecified,,,,,Change in heart rate after iv administration of 0.108 uM/kg in anesthetized rats,Other,10447956.0,
496,196038,6,4,,103189246,2803,Unspecified,,,20.0,IC50,Inhibitory activity against norepinephrine (NE) uptake in rat whole brain synaptosome preparation,Confirmatory,8558529.0,
497,197166,3,4,,103189246,2803,Unspecified,,,,,Hypotensive activity measured as the 20% decrease in mean arterial blood pressure in anesthetized normotensive rat,Other,7143348.0,
498,197167,3,3,,103189246,2803,Unspecified,,,,,Hypotensive activity (25% decrease in arterial pressure) after i.v. administration to anesthetized normotensive rats.,Other,6142954.0,
499,197169,3,3,,103189246,2803,Unspecified,,,,,Hypertensive activity (increase in arterial pressure to 60 mmHg)) after i.v. administration to pithed rats.,Other,6142954.0,
500,197287,3,4,,103189246,2803,Unspecified,,,,,Change in systolic Blood prusers following iv administration at (0.108 umol/kg)anesthetized rats,Other,11520203.0,
501,197293,3,4,,103189246,2803,Unspecified,,,,,Changes in diastolic Blood prusers following iv administration at (0.108 umol/kg)anesthetized rats,Other,11520203.0,
502,202892,11,1,,103189246,2803,Unspecified,,,900.0,Ki,Inhibitory activity against porcine kidney amine oxidase,Confirmatory,11551750.0,
503,218803,3,9,,103189246,2803,Unspecified,,,,,Alpha-2 adrenergic receptor activity in guinea pig right atrium,Other,,
504,219808,9,2,,103189246,2803,Active,,,0.0173,IC50,Compound was tested for its ability to inhibit specific binding of [3H]-clonidine to alpha-2-adrenoceptor.,Confirmatory,2879913.0,
505,223225,7,3,,103189246,2803,Active,,,0.0089,Ki,Displacement of [3H]-clonidine from bovine imidazoline receptor I-1,Confirmatory,8632424.0,
506,223226,7,5,,103189246,2803,Active,296439287.0,11188.0,0.01,Ki,Binding affinity for imidazoline receptor I-1,Confirmatory,7562902.0,
507,223241,4,10,,103189246,2803,Unspecified,113978.0,4128.0,0.1,Ki,Binding affinity for imidazoline receptor I-2,Confirmatory,7562902.0,
508,223241,4,10,,103189246,2803,Unspecified,113980.0,4129.0,0.1,Ki,Binding affinity for imidazoline receptor I-2,Confirmatory,7562902.0,
509,223358,4,7,,103189246,2803,Unspecified,,,,,Intrinsic activity expressed as ratio of maximum responses to the compound to the maximum response to clonidine in guinea pig vas deferens.,Other,1956038.0,
510,223928,3,3,,103189246,2803,Unspecified,,,,,potential antinociceptive activity initially at a screening dose of 30 mg/kg po in the mouse abdominal irritant test(MAIT) using acetylcholine bromide as irritant,Other,10753480.0,
511,225282,6,2,,103189246,2803,Unspecified,,,,,ED50 value was measured using rat air-induced abdominal irritant test(RAIT),Other,10753480.0,
512,227718,7,1,,103189246,2803,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
513,229655,3,10,,103189246,2803,Unspecified,231461.0,25083.0,,,Relative affinities for Alpha1 and alpha-2 adrenergic receptors in rat,Other,2864446.0,
514,229655,3,10,,103189246,2803,Unspecified,231464.0,24175.0,,,Relative affinities for Alpha1 and alpha-2 adrenergic receptors in rat,Other,2864446.0,
515,229655,3,10,,103189246,2803,Unspecified,543734.0,24173.0,,,Relative affinities for Alpha1 and alpha-2 adrenergic receptors in rat,Other,2864446.0,
516,229655,3,10,,103189246,2803,Unspecified,1168244.0,29413.0,,,Relative affinities for Alpha1 and alpha-2 adrenergic receptors in rat,Other,2864446.0,
517,229655,3,10,,103189246,2803,Unspecified,1168247.0,29412.0,,,Relative affinities for Alpha1 and alpha-2 adrenergic receptors in rat,Other,2864446.0,
518,229655,3,10,,103189246,2803,Unspecified,47117345.0,24174.0,,,Relative affinities for Alpha1 and alpha-2 adrenergic receptors in rat,Other,2864446.0,
519,232721,3,5,,103189246,2803,Unspecified,,,,,Selectivity ratio of alpha1/alpha2d,Other,10715142.0,
520,234208,4,4,,103189246,2803,Unspecified,,,,,Therapeutic ratio is oral dose producing sedation/reduction in blood pressure,Other,7452693.0,
521,234209,3,4,,103189246,2803,Unspecified,,,,,Therapeutic ratio is oral dose producing sedation/reduction in blood pressure; Range is 0.8-1.7,Other,7452693.0,
522,243661,3,9,,103189246,2803,Unspecified,112821.0,3351.0,,,Percent displacement of radioligand from human 5-hydroxytryptamine 1B receptor at 1000 nM,Other,15324890.0,
523,243662,3,10,,103189246,2803,Unspecified,112819.0,3352.0,,,Percent displacement of radioligand from human 5-hydroxytryptamine 1D receptor at 1000 nM,Other,15324890.0,
524,288184,9,1,,103189246,2803,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
525,288185,7,1,,103189246,2803,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
526,288192,3,4,,103189246,2803,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
527,297456,4,1,,103189246,2803,Active,1351829.0,150.0,0.02089,Ki,Displacement of [3H]RX821002 from adrenergic alpha2 receptor in human brain frontal cortex,Confirmatory,17691718.0,
528,297456,4,1,,103189246,2803,Active,20141211.0,152.0,0.02089,Ki,Displacement of [3H]RX821002 from adrenergic alpha2 receptor in human brain frontal cortex,Confirmatory,17691718.0,
529,297456,4,1,,103189246,2803,Active,613504690.0,151.0,0.02089,Ki,Displacement of [3H]RX821002 from adrenergic alpha2 receptor in human brain frontal cortex,Confirmatory,17691718.0,
530,311367,3,6,,103189246,2803,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
531,311524,4,3,,103189246,2803,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
532,327870,3,10,,103189246,2803,Inactive,2851402.0,4988.0,,,Activation of human mu opioid receptor expressed in HEK293a cells coexpressing YFP-labelled alphai1 and CFP-labelled beta-1-gamma-2 Gi subunits assessed as decrease in fluorescence resonance energy transfer signal,Other,17616524.0,
533,342860,5,2,,103189246,2803,Active,,,0.0165,Ki,Displacement of [125I]PIC from human alpha2 adrenoceptors expressed in CHO cells,Confirmatory,18621536.0,
534,342861,11,2,,103189246,2803,Active,296439287.0,11188.0,0.05495,Ki,Displacement of [125I]PIC from human imidazoline receptor 1 in human platelets analyzed under norepinephrine mask of alpha 2AR,Confirmatory,18621536.0,
535,342863,3,3,,103189246,2803,Unspecified,,,,,Selectivity ratio of pKi for human imidazoline receptor 1 to pKi for human alpha2 adrenoceptors,Other,18621536.0,
536,349880,8,1,,103189246,2803,Unspecified,,,,,Permeability across porcine brain lipid coated polyvinylidene fluoride membrane by PAMPA,Other,19374444.0,
537,364880,5,3,,103189246,2803,Active,,,0.02089,Ki,Displacement of [3H]RX821002 from alpha2 adrenoceptor in human prefrontal cortex neural membrane,Confirmatory,18678494.0,
538,368169,3,4,,103189246,2803,Unspecified,,,,,Displacement of [3H]RX821002 from alpha2 adrenoceptor in human prefrontal cortex neural membrane after 30 mins by liquid scintillation spectrometry,Other,19133776.0,
539,371645,8,5,,103189246,2803,Active,205829312.0,306255.0,0.3662,IC50,Displacement of [3H]clonidine from imidazoline I1 receptor in Sprague-Dawley rat kidney by liquid scintillation counting,Confirmatory,19101144.0,
540,371646,4,3,,103189246,2803,Active,,,0.3645,Ki,Displacement of [3H]2BFI from imidazoline I2 receptor in Sprague-Dawley rat brain by liquid scintillation counting,Confirmatory,19101144.0,
541,371647,4,4,,103189246,2803,Active,,,0.0087,Ki,Displacement of [3H]RX821002 from alpha2 adrenoceptor in Sprague-Dawley rat kidney by liquid scintillation counting,Confirmatory,19101144.0,
542,386232,3,8,,103189246,2803,Unspecified,,,,,Antagonist activity at mu opioid receptor expressed in HEK293 cells assessed as blockade of secreted alkaline phosphatase activity at 1 uM after 6 hrs relative to control,Other,18077343.0,
543,386623,4,8,,103189246,2803,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
544,386625,9,5,,103189246,2803,Active,313104181.0,6580.0,22.6,IC50,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy,Confirmatory,18788725.0,
545,395325,3,3,,103189246,2803,Unspecified,,,,,"Lipophilicity, log P by microemulsion electrokinetic chromatography",Other,19256501.0,
546,395328,3,3,,103189246,2803,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,19256501.0,
547,404330,5,2,,103189246,2803,Active,,,0.02089,Ki,Displacement of [3H]RX821002 from alpha2 adrenergic receptor in human brain prefrontal cortex tissue by liquid scintillation spectrometry,Confirmatory,18459731.0,
548,425652,7,2,,103189246,2803,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
549,425653,7,2,,103189246,2803,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
550,427196,8,1,,103189246,2803,Unspecified,,,,,Membrane permeability by PAMPA-BBB assay,Other,19663388.0,
551,427197,8,1,,103189246,2803,Unspecified,,,,,Membrane permeability dissolved in PBS/EtOH (70:30) mixture by PAMPA-BBB assay,Other,19663388.0,
552,427198,8,1,,103189246,2803,Unspecified,,,,,Membrane permeability dissolved in PBS/EtOH (80:20) mixture by PAMPA-BBB assay,Other,19663388.0,
553,434959,1,1,,85787756,2803,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
554,434959,1,1,,85788378,2803,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
555,455986,3,5,,103189246,2803,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
556,463106,1,2,,90341662,2803,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
557,467611,3,6,,103189246,2803,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
558,467612,3,6,,103189246,2803,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
559,467613,5,3,,103189246,2803,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
560,468443,4,7,,103189246,2803,Unspecified,60416391.0,2166.0,,,Inhibition of human FAAH at 1 uM,Other,19850474.0,
561,469403,5,1,,103189246,2803,Unspecified,,,,,Permeability across PAMPA membrane,Other,19856923.0,
562,476929,3,3,,103189246,2803,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
563,485281,1,1,,11110985,2803,Inactive,254220970.0,,5.0119,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
564,485290,1,1,,11110985,2803,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
565,485290,1,1,,11113648,2803,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
566,485290,1,1,,26751841,2803,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
567,485290,1,1,,26751842,2803,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
568,485295,1,2,,90341662,2803,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
569,485297,1,1,,90341662,2803,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
570,485298,1,1,,90341662,2803,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
571,485313,1,2,,90341662,2803,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
572,485342,1,2,,90341662,2803,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
573,485345,1,2,,90341662,2803,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
574,485350,1,2,,99300916,2803,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
575,485366,1,2,,90341662,2803,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
576,485368,1,2,,90341662,2803,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
577,488772,1,1,,90341662,2803,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
578,488773,1,2,,90341662,2803,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
579,488816,1,1,,90341662,2803,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
580,488837,1,1,,90341662,2803,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
581,488949,1,2,,90341662,2803,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
582,488953,1,1,,90341662,2803,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
583,488978,1,1,,90341662,2803,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
584,488981,1,1,,90341662,2803,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
585,488982,1,1,,90341662,2803,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
586,488983,1,1,,90341662,2803,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
587,493033,1,2,,99300916,2803,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
588,493106,1,1,,90341662,2803,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
589,493107,1,1,,90341662,2803,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
590,493153,1,1,,90341662,2803,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
591,493153,1,1,,90341662,2803,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
592,493162,1,2,,99302436,2803,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
593,493164,1,2,,90341662,2803,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
594,493164,1,2,,90341662,2803,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
595,493164,1,2,,90341662,2803,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
596,496817,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
597,496818,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
598,496819,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
599,496820,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
600,496821,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
601,496823,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
602,496824,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
603,496825,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
604,496826,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
605,496827,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
606,496828,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
607,496829,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
608,496830,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
609,496831,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
610,496832,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
611,497005,4,2,,103189246,2803,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
612,503832,2,6,,103189246,2803,Active,,,,,Partial agonist activity at adrenergic alpha2A receptor expressed in HEK293 cells coexpressing yellow fluorescent and cyan fluorescent protein assessed as effect on kinetics of receptor conformational change by FRET assay,Other,16407989.0,
613,504327,1,1,,11110985,2803,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
614,504327,1,1,,90341662,2803,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
615,504332,1,1,,11110985,2803,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
616,504332,1,1,,90341662,2803,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
617,504536,1,1,,90341662,2803,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
618,504547,1,1,,90341662,2803,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
619,504548,1,2,,90341662,2803,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
620,504749,1,3,,26751841,2803,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
621,504749,1,3,,104171138,2803,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
622,504749,1,3,1.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
623,504749,1,3,2.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
624,504749,1,3,3.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
625,504749,1,3,4.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
626,504749,1,3,5.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
627,504749,1,3,6.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
628,504749,1,3,7.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
629,504749,1,3,8.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
630,504749,1,3,9.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
631,504749,1,3,10.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
632,504749,1,3,11.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
633,504749,1,3,12.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
634,504749,1,3,13.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
635,504749,1,3,14.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
636,504749,1,3,15.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
637,504749,1,3,16.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
638,504749,1,3,17.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
639,504749,1,3,18.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
640,504749,1,3,19.0,26751841,2803,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
641,504749,1,3,20.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
642,504749,1,3,21.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
643,504749,1,3,22.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
644,504749,1,3,23.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
645,504749,1,3,24.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
646,504749,1,3,25.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
647,504749,1,3,26.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
648,504749,1,3,27.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
649,504749,1,3,28.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
650,504749,1,3,29.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
651,504749,1,3,30.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
652,504749,1,3,31.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
653,504749,1,3,32.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
654,504749,1,3,33.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
655,504749,1,3,34.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
656,504749,1,3,35.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
657,504749,1,3,36.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
658,504749,1,3,37.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
659,504749,1,3,38.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
660,504749,1,3,39.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
661,504749,1,3,40.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
662,504749,1,3,41.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
663,504749,1,3,42.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
664,504749,1,3,43.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
665,504749,1,3,44.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
666,504749,1,3,45.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
667,504749,1,3,46.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
668,504749,1,3,47.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
669,504749,1,3,48.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
670,504749,1,3,49.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
671,504749,1,3,50.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
672,504749,1,3,51.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
673,504749,1,3,52.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
674,504749,1,3,53.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
675,504749,1,3,54.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
676,504749,1,3,55.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
677,504749,1,3,56.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
678,504749,1,3,57.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
679,504749,1,3,58.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
680,504749,1,3,59.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
681,504749,1,3,60.0,104171138,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
682,504749,1,3,61.0,26751841,2803,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
683,504810,1,2,,90341662,2803,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
684,504812,1,2,,90341662,2803,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
685,504832,1,1,,104171138,2803,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
686,504834,1,1,,104171138,2803,Active,,,11.9955,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
687,504836,1,2,,90341662,2803,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
688,504845,1,1,,90341662,2803,Inactive,86301163.0,5999.0,21.1923,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
689,504845,1,1,,104171138,2803,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
690,504847,1,1,,11110985,2803,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
691,504847,1,1,,90341662,2803,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
692,504847,1,1,,104171138,2803,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
693,504865,1,1,,11110985,2803,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
694,504865,1,1,,90341662,2803,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
695,504865,1,1,,104171138,2803,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
696,513626,2,4,,103189246,2803,Active,,,,,Induction of autophagy in rat stable inducible PC12 cells expressing A53T alpha-synuclein assessed as A53T alpha-synuclein clearance at 1 uM after 24 hrs by densitometric analysis,Other,18391949.0,
697,513627,2,4,,103189246,2803,Active,,,,,Induction of autophagy in rat stable inducible PC12 cells expressing EGFP-HDQ74 assessed as soluble EGFP-HDQ74 clearance at 1 uM after 96 hrs by densitometric analysis,Other,18391949.0,
698,513628,1,4,,103189246,2803,Active,,,,,Induction of autophagy in human SK-N-MC cells expressing EGFP-HDQ74 assessed as reduction in EGFP-HDQ74 aggregation at 1 uM after 48 hrs by densitometric analysis,Other,18391949.0,
699,513629,1,4,,103189246,2803,Unspecified,,,,,Cytotoxicity against human SK-N-MC cells expressing EGFP-HDQ74 at 1 uM after 48 hrs,Other,18391949.0,
700,513631,1,4,,103189246,2803,Active,,,,,Induction of autophagy in human SK-N-MC cells assessed as increase in LC3-2 level at 1 uM after 24 hrs by immunoblotting analysis,Other,18391949.0,
701,513633,2,3,,103189246,2803,Inactive,,,,,Induction of autophagy in Atg deficient mouse MFF expressing EGFP-HDQ74 at 1 uM after 48 hrs,Other,18391949.0,
702,513635,1,4,,103189246,2803,Active,,,,,Induction of autophagy in Atg positive human SK-N-MC cells expressing EGFP-HDQ74 at 1 uM after 48 hrs,Other,18391949.0,
703,513655,1,4,,103189246,2803,Inactive,,,,,Induction of autophagy in human SK-N-SH cells expressing EGFP-HDQ74/m-calpain assessed as inhibition of EGFP-HDQ74 aggregation at 1 uM after 48 hrs,Other,18391949.0,
704,514302,1,3,,103189246,2803,Active,,,,,Protection of neurodegeneration in zebrafish Huntington's disease model expressing EGFP-tagged huntingtin exon with EGFP-HDQ71 in rod photoreceptor assessed as decrease in EGFP-HDQ74 aggregation at 10 uM,Other,18391949.0,
705,514303,1,3,,103189246,2803,Inactive,,,,,Protection of neurodegeneration in zebrafish Huntington's disease model expressing EGFP-tagged huntingtin exon with EGFP-HDQ71 in rod photoreceptor assessed as loss of rhodopsin expression at 10 uM,Other,18391949.0,
706,514304,1,3,,103189246,2803,Active,,,,,Protection of neurodegeneration in zebrafish Huntington's disease model expressing EGFP-tagged huntingtin exon with EGFP-HDQ71 in rod photoreceptor assessed as decrease in EGFP-HDQ74 aggregation at 3 uM,Other,18391949.0,
707,514306,1,3,,103189246,2803,Active,,,,,Protection of neurodegeneration in zebrafish Huntington's disease model expressing EGFP-tagged huntingtin exon with EGFP-HDQ71 in rod photoreceptor assessed as induction of rhodopsin expression at 3 uM,Other,18391949.0,
708,536933,5,6,,103189246,2803,Active,1351829.0,150.0,0.008320000000000001,EC50,Agonist activity at human alpha2A adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry,Confirmatory,20925410.0,
709,536934,2,10,,103189246,2803,Unspecified,1351829.0,150.0,,,Agonist activity at human alpha2A adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry relative to (-)noradrenaline,Other,20925410.0,
710,536937,6,1,,103189246,2803,Active,613504690.0,151.0,1.1749,EC50,Agonist activity at human alpha2B adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry,Confirmatory,20925410.0,
711,536938,2,10,,103189246,2803,Unspecified,613504690.0,151.0,,,Agonist activity at human alpha2B adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry relative to (-)noradrenaline,Other,20925410.0,
712,536941,5,6,,103189246,2803,Active,20141211.0,152.0,0.05754,EC50,Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry,Confirmatory,20925410.0,
713,536942,2,11,,103189246,2803,Unspecified,20141211.0,152.0,,,Agonist activity at human Alpha-2C adrenoceptor expressed in CHO cells assessed as induction of extracellular acidification by microphysiometry relative to (-)noradrenaline,Other,20925410.0,
714,536949,2,4,,103189246,2803,Active,,,,,"Reduction in morphine dependence expression in CD1 mouse assessed as decrease in expression of naloxone-precipitated withdrawal syndrome at 5 mg/kg, ip administered as single dose 15 mins before last morphine dosing on test day post morphine challenge by radiant heat tail flick test",Other,20925410.0,
715,536950,2,4,,103189246,2803,Active,,,,,"Reduction in morphine tolerance acquisition in CD1 mouse assessed as morphine analgesic effect incidence at 2 mg/kg, ip administered as single dose 15 mins before last morphine dosing on test day post morphine challenge by radiant heat tail flick test",Other,20925410.0,
716,536951,2,4,,103189246,2803,Unspecified,,,,,Toxicity in CD1 mouse assessed as induction of sedation by pentobarbital sodium induced sleep time assay,Other,20925410.0,
717,536952,2,4,,103189246,2803,Unspecified,,,,,Toxicity in CD1 mouse assessed as induction of hypotension by pentobarbital sodium induced sleep time assay,Other,20925410.0,
718,540209,4,3,,103189246,2803,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
719,540210,4,3,,103189246,2803,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
720,540211,2,5,,103189246,2803,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
721,540212,4,3,,103189246,2803,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
722,540213,4,3,,103189246,2803,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
723,540256,1,2,,90341662,2803,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
724,540276,1,2,,11110984,2803,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
725,540276,1,2,,11110985,2803,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
726,540276,1,2,,11113648,2803,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
727,540276,1,2,,26751841,2803,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
728,540276,1,2,,26751842,2803,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
729,540276,1,2,,50104544,2803,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
730,540276,1,2,,50124402,2803,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
731,540276,1,2,,90341662,2803,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
732,540299,1,2,,99302436,2803,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
733,550035,7,1,,103189246,2803,Active,1351829.0,150.0,0.027999999999999997,EC50,Agonist activity at human recombinant alpha2A adrenergic receptor expressed in CHO cells assessed as induction of [35S]GTPgammaS binding after 60 mins by scintillation counting,Confirmatory,21129985.0,
734,550036,2,10,,103189246,2803,Unspecified,1351829.0,150.0,,,Agonist activity at human recombinant alpha2A adrenergic receptor expressed in CHO cells assessed as induction of [35S]GTPgammaS binding after 60 mins by scintillation counting relative to noradrenaline,Other,21129985.0,
735,552772,6,5,,103189246,2803,Active,205829312.0,306255.0,0.3662,IC50,Inhibition of Sprague-Dawley rat imidazoline I1 receptor,Confirmatory,21159515.0,
736,552773,3,3,,103189246,2803,Active,,,0.3645,Ki,Inhibition of Sprague-Dawley rat imidazoline I2 receptor,Confirmatory,21159515.0,
737,552774,3,3,,103189246,2803,Active,,,0.0087,Ki,Inhibition of Sprague-Dawley rat alpha-2 adrenergic receptor,Confirmatory,21159515.0,
738,569427,1,4,,103189246,2803,Unspecified,,,,,Antihypertensive activity in cat assessed as change in blood pressure at 10 mg/kg measured within 5 mins,Other,21232951.0,
739,569428,1,4,,103189246,2803,Unspecified,,,,,Antihypertensive activity in cat assessed as change in blood pressure at 10 mg/kg measured after 5 mins,Other,21232951.0,
740,569431,1,4,,103189246,2803,Unspecified,,,,,Antihypertensive activity in cat assessed as change in heart rate at 10 mg/kg measured within 5 mins,Other,21232951.0,
741,569432,1,4,,103189246,2803,Unspecified,,,,,Antihypertensive activity in cat assessed as change in heart rate at 10 mg/kg measured after 5 mins,Other,21232951.0,
742,588211,2,3,,103189246,2803,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
743,588212,2,3,,103189246,2803,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
744,588213,2,3,,103189246,2803,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
745,588214,2,3,,103189246,2803,Active,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
746,588215,2,3,,103189246,2803,Active,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
747,588216,2,3,,103189246,2803,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
748,588217,2,3,,103189246,2803,Active,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
749,588218,2,3,,103189246,2803,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
750,588219,2,3,,103189246,2803,Active,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
751,588220,2,3,,103189246,2803,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
752,588349,1,1,,90341662,2803,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
753,588378,1,1,,90341662,2803,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
754,588379,1,2,,124879741,2803,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
755,588453,1,1,,90341662,2803,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
756,588456,1,1,,90341662,2803,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
757,588519,1,2,,99300916,2803,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
758,588519,1,2,,99302436,2803,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
759,588579,1,1,,11110985,2803,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
760,588579,1,1,,90341662,2803,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
761,588579,1,1,,104171138,2803,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
762,588579,1,1,,124879741,2803,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
763,588579,1,1,,124879743,2803,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
764,588795,1,1,,90341662,2803,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
765,588834,2,1,,26751841,2803,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
766,592681,1,4,,103189246,2803,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
767,602314,1,2,,99300916,2803,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
768,602332,1,1,,11110985,2803,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
769,602332,1,1,,90341662,2803,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
770,602332,1,1,,104171138,2803,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
771,602332,1,1,,124879741,2803,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
772,602332,1,1,,124879743,2803,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
773,620399,3,1,,103189246,2803,Unspecified,,,,,Permeability of the compound by PAMPA,Other,21871694.0,
774,624030,1,2,,104171138,2803,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
775,624031,1,2,,104171138,2803,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
776,624032,1,2,,104171138,2803,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
777,624044,1,2,,104171138,2803,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
778,624146,1,1,,90341662,2803,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
779,624147,1,1,,90341662,2803,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
780,624148,1,2,,90341662,2803,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
781,624149,1,1,,90341662,2803,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
782,624156,1,1,,85787756,2803,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
783,624156,1,1,,85788378,2803,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
784,624170,1,1,,104171138,2803,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
785,624172,1,1,,104171138,2803,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
786,624173,1,3,,104171138,2803,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
787,624296,1,1,,26751841,2803,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
788,624296,1,1,,104171138,2803,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
789,624297,1,1,,26751841,2803,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
790,624297,1,1,,104171138,2803,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
791,624349,1,2,,92308807,2803,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
792,624455,1,1,,90341662,2803,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
793,625144,5,5,,103189246,2803,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
794,625145,4,7,,103189246,2803,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
795,625146,5,5,,103189246,2803,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
796,625147,4,7,,103189246,2803,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
797,625148,4,7,,103189246,2803,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
798,625149,4,7,,103189246,2803,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
799,625150,5,5,,103189246,2803,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
800,625151,4,7,,103189246,2803,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
801,625152,4,7,,103189246,2803,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
802,625153,4,7,,103189246,2803,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
803,625154,4,7,,103189246,2803,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
804,625155,4,7,,103189246,2803,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
805,625156,1,9,,103189246,2803,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
806,625157,6,2,,103189246,2803,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
807,625158,3,4,,103189246,2803,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
808,625159,5,5,,103189246,2803,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
809,625160,1,9,,103189246,2803,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
810,625161,4,7,,103189246,2803,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
811,625162,4,7,,103189246,2803,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
812,625163,4,7,,103189246,2803,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
813,625164,1,6,,103189246,2803,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
814,625165,3,4,,103189246,2803,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
815,625166,3,4,,103189246,2803,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
816,625167,5,5,,103189246,2803,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
817,625168,4,7,,103189246,2803,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
818,625169,1,6,,103189246,2803,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
819,625170,3,4,,103189246,2803,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
820,625171,4,7,,103189246,2803,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
821,625172,4,7,,103189246,2803,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
822,625173,5,5,,103189246,2803,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
823,625174,5,5,,103189246,2803,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
824,625175,5,5,,103189246,2803,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
825,625176,1,9,,103189246,2803,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
826,625177,5,5,,103189246,2803,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
827,625178,5,5,,103189246,2803,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
828,625179,1,9,,103189246,2803,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
829,625180,5,5,,103189246,2803,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
830,625181,5,5,,103189246,2803,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
831,625182,5,5,,103189246,2803,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
832,625183,5,5,,103189246,2803,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
833,625184,5,5,,103189246,2803,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
834,625185,5,5,,103189246,2803,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
835,625186,5,5,,103189246,2803,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
836,625187,5,5,,103189246,2803,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
837,625188,1,9,,103189246,2803,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
838,625189,1,7,,103189246,2803,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
839,625190,4,5,,103189246,2803,Active,,,5.365,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
840,625191,4,7,,103189246,2803,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
841,625192,4,7,,103189246,2803,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
842,625193,5,5,,103189246,2803,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
843,625194,4,7,,103189246,2803,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
844,625195,4,7,,103189246,2803,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
845,625196,5,6,,103189246,2803,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
846,625197,3,4,,103189246,2803,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
847,625198,4,7,,103189246,2803,Active,1168247.0,29412.0,0.37200000000000005,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
848,625199,4,7,,103189246,2803,Active,543734.0,24173.0,1.848,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
849,625200,4,7,,103189246,2803,Active,1168243.0,146.0,1.21,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
850,625201,4,7,,103189246,2803,Active,1351829.0,150.0,0.28,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
851,625202,4,7,,103189246,2803,Active,613504690.0,151.0,0.083,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
852,625203,4,7,,103189246,2803,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
853,625204,4,7,,103189246,2803,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
854,625205,4,7,,103189246,2803,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
855,625206,4,7,,103189246,2803,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
856,625207,4,7,,103189246,2803,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
857,625208,5,5,,103189246,2803,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
858,625209,4,7,,103189246,2803,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
859,625210,3,4,,103189246,2803,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
860,625211,1,6,,103189246,2803,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
861,625212,3,4,,103189246,2803,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
862,625213,4,7,,103189246,2803,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
863,625214,1,9,,103189246,2803,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
864,625215,3,4,,103189246,2803,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
865,625216,3,4,,103189246,2803,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
866,625217,4,7,,103189246,2803,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
867,625218,4,7,,103189246,2803,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
868,625219,3,4,,103189246,2803,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
869,625220,4,7,,103189246,2803,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
870,625221,4,7,,103189246,2803,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
871,625222,4,7,,103189246,2803,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
872,625223,4,7,,103189246,2803,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
873,625224,3,4,,103189246,2803,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
874,625225,3,4,,103189246,2803,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
875,625226,4,7,,103189246,2803,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
876,625227,4,7,,103189246,2803,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
877,625228,4,7,,103189246,2803,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
878,625229,5,5,,103189246,2803,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
879,625230,1,6,,103189246,2803,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
880,625231,4,7,,103189246,2803,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
881,625232,1,9,,103189246,2803,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
882,625233,4,7,,103189246,2803,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
883,625234,3,4,,103189246,2803,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
884,625235,4,7,,103189246,2803,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
885,625236,5,5,,103189246,2803,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
886,625237,4,7,,103189246,2803,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
887,625238,4,7,,103189246,2803,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
888,625239,4,7,,103189246,2803,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
889,625240,1,9,,103189246,2803,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
890,625241,4,7,,103189246,2803,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
891,625242,4,7,,103189246,2803,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
892,625243,5,5,,103189246,2803,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
893,625244,5,5,,103189246,2803,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
894,625245,5,5,,103189246,2803,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
895,625246,1,9,,103189246,2803,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
896,625247,5,5,,103189246,2803,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
897,625248,5,5,,103189246,2803,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
898,625249,5,5,,103189246,2803,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
899,625250,5,5,,103189246,2803,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
900,625251,5,5,,103189246,2803,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
901,625252,4,7,,103189246,2803,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
902,625253,4,7,,103189246,2803,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
903,625254,4,7,,103189246,2803,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
904,625255,4,7,,103189246,2803,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
905,625256,4,7,,103189246,2803,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
906,625257,4,7,,103189246,2803,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
907,625258,4,7,,103189246,2803,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
908,625259,4,7,,103189246,2803,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
909,625260,3,4,,103189246,2803,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
910,625261,3,4,,103189246,2803,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
911,625262,3,4,,103189246,2803,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
912,625263,4,7,,103189246,2803,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
913,625264,3,4,,103189246,2803,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
914,625265,1,6,,103189246,2803,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
915,625266,3,4,,103189246,2803,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
916,625267,3,4,,103189246,2803,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
917,625268,4,2,,103189246,2803,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
918,625268,4,2,,103189246,2803,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
919,625268,4,2,,103189246,2803,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
920,625268,4,2,,103189246,2803,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
921,625269,4,7,,103189246,2803,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
922,625270,4,7,,103189246,2803,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
923,625271,5,5,,103189246,2803,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
924,625272,3,4,,103189246,2803,Active,,,0.064,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
925,625273,4,6,,103189246,2803,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
926,625274,1,6,,103189246,2803,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
927,625275,3,4,,103189246,2803,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
928,625277,1,3,,103189246,2803,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
929,625279,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
930,625280,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
931,625281,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
932,625282,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
933,625283,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
934,625284,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
935,625285,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
936,625286,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
937,625287,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
938,625288,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
939,625289,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
940,625290,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
941,625291,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
942,625292,1,3,,103189246,2803,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
943,636210,5,1,,103189246,2803,Active,1351829.0,150.0,0.03,EC50,Agonist activity at human adrenoceptor alpha2A expressed in CHOK1 cells assessed as stimulation of agonist-induced [35S]GTPgammaS binding by scintillation counting,Confirmatory,22172308.0,
944,636211,1,9,,103189246,2803,Unspecified,1351829.0,150.0,,,Agonist activity at human adrenoceptor alpha2A expressed in CHOK1 cells assessed as stimulation of agonist-induced [35S]GTPgammaS binding by scintillation counting assay relative to noradrenaline,Other,22172308.0,
945,639368,3,1,,103189246,2803,Unspecified,,,,,Permeability of the compound by PAMPA assay,Other,21420206.0,
946,648667,3,1,,103189246,2803,Unspecified,,,,,Permeability of the compound in porcine brain lipid assessed as ratio of compound in acceptor plate to amount of compound in donor plate at 5 mg/ml after 10 hrs by PAMPA assay,Other,22341944.0,
947,651631,4,1,,144203669,2803,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
948,651632,4,1,,144203669,2803,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
949,651633,4,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
950,651634,4,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
951,651635,1,3,,11110985,2803,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
952,651635,1,3,,90341662,2803,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
953,651828,1,2,,92308807,2803,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
954,652048,1,2,,144203669,2803,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
955,652051,1,1,,144203669,2803,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
956,652106,1,1,,90341662,2803,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
957,671632,4,5,,103189246,2803,Active,205829312.0,306255.0,0.28184000000000003,Ki,Displacement of [3H]paraiodoclonidine from imidazoline I1 receptor in rat PC12 cells after 30 mins by gamma counter,Confirmatory,22750139.0,
958,671633,2,2,,103189246,2803,Unspecified,,,10.0,Ki,Displacement of [3H]idazoxan from imidazoline I2 receptor in New Zealand rabbit renal cortex homogenate after 60 mins by gamma counter,Confirmatory,22750139.0,
959,671634,5,5,,103189246,2803,Active,1351829.0,150.0,0.008709999999999999,Ki,Displacement of [3H]RX821001 from human alpha2A adrenoceptor expressed in CHO cells after 60 mins by gamma counter,Confirmatory,22750139.0,
960,671635,5,5,,103189246,2803,Active,613504690.0,151.0,0.03162,Ki,Displacement of [3H]RX821001 from human alpha2B adrenoceptor expressed in CHO cells after 60 mins by gamma counter,Confirmatory,22750139.0,
961,671636,5,5,,103189246,2803,Active,20141211.0,152.0,0.00933,Ki,Displacement of [3H]RX821001 from human alpha2C adrenoceptor expressed in CHO cells after 60 mins by gamma counter,Confirmatory,22750139.0,
962,679482,3,6,,103189246,2803,Unspecified,24212063.0,6581.0,79.3,IC50,TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.2 uM) in OCT3-expressing HEK293 cells,Confirmatory,11191835.0,
963,680406,1,8,,103189246,2803,Unspecified,146345508.0,6583.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, Clonidine: 1000 uM) in Xenopus laevis oocytes",Other,10215651.0,
964,680959,1,7,,103189246,2803,Unspecified,24212075.0,20519.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Clonidine: 5000 uM) in OCT3-expressing HRPE cells",Other,10966924.0,
965,681117,3,6,,103189246,2803,Unspecified,313104181.0,6580.0,,IC50,TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells,Confirmatory,12606755.0,
966,681118,1,8,,103189246,2803,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in Caco-2 cells,Other,12954186.0,
967,681146,3,6,,103189246,2803,Unspecified,313104181.0,6580.0,0.55,Ki,TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells,Confirmatory,9655880.0,
968,681376,3,6,,103189246,2803,Unspecified,81872095.0,24904.0,1.4,Ki,TP_TRANSPORTER: inhibition of MPP+ uptake in OCT1-expressing HEK293 cells,Confirmatory,8878062.0,
969,681584,3,6,,103189246,2803,Unspecified,24212063.0,6581.0,373.0,Ki,TP_TRANSPORTER: inhibition of MPP+ uptake in OCT3-expressing HRPE cells,Confirmatory,10966924.0,
970,681678,1,7,,103189246,2803,Unspecified,8928257.0,6584.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Clonidine: 500 uM) in OCTN2-expressing HEK293 cells",Other,10525100.0,
971,681705,1,7,,103189246,2803,Unspecified,8928242.0,29726.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Clonidine: 2500 uM) in OCTN2-expressing HRPE cells",Other,10454528.0,
972,681955,1,7,,103189246,2803,Unspecified,313104181.0,6580.0,,,"TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.85 uM, Clonidine: 5000 uM) in Xenopus laevis oocytes",Other,9187257.0,
973,682996,5,5,,103189246,2803,Active,231454.0,3350.0,3.2359400000000003,Ki,Displacement of [3H]8-OH-DPAT from human 5HT1A receptor expressed in HeLa cells after 30 mins,Confirmatory,24900506.0,
974,686977,2,1,,49699311,2803,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
975,686978,1,1,,124879741,2803,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
976,686978,1,1,,124879743,2803,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
977,686978,1,1,,144203669,2803,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
978,686979,1,1,,124879741,2803,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
979,686979,1,1,,124879743,2803,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
980,686979,1,1,,144203669,2803,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
981,720516,2,1,,144203669,2803,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
982,720532,1,1,,11110985,2803,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
983,720532,1,1,,124879741,2803,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
984,720532,1,1,,124879743,2803,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
985,720532,1,1,,144203669,2803,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
986,720533,1,1,,11110985,2803,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
987,720533,1,1,,124879741,2803,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
988,720533,1,1,,124879743,2803,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
989,720533,1,1,,144203669,2803,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
990,720538,1,2,,90341662,2803,Inconclusive,220983390.0,410.0,0.0426,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
991,720552,2,1,,144203669,2803,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
992,720559,1,2,,90341662,2803,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
993,720572,1,2,,90341662,2803,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
994,720573,1,2,,90341662,2803,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
995,720579,2,1,,124879743,2803,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
996,720580,1,1,,124879743,2803,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
997,720634,2,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
998,720635,2,1,,144203669,2803,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
999,720637,2,1,,144203669,2803,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1000,720641,1,2,,92308807,2803,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
1001,720674,2,2,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1002,720675,2,2,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1003,720678,2,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1004,720679,2,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1005,720680,2,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1006,720681,2,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1007,720682,2,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1008,720683,2,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1009,720684,2,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1010,720685,2,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1011,720686,2,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1012,720687,2,2,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1013,720691,4,1,,144203669,2803,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1014,720692,3,1,,144203669,2803,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1015,720693,3,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1016,720717,1,3,,92308807,2803,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1017,720717,1,3,,92310004,2803,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1018,720719,2,1,,144203669,2803,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1019,720725,2,1,,144203669,2803,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1020,721753,1,6,,103189246,2803,Unspecified,74731723.0,55244.0,,,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay,Other,23241029.0,
1021,721754,2,5,,103189246,2803,Active,74731723.0,55244.0,33.3,IC50,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
1022,727731,1,3,,103189246,2803,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 3 to 12 by UV spectroscopy",Other,24900577.0,
1023,743012,3,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1024,743014,3,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1025,743015,3,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1026,743033,3,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1027,743035,2,1,,144203669,2803,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1028,743036,2,1,,144203669,2803,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1029,743040,3,1,,144203669,2803,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1030,743041,3,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1031,743042,3,1,,144203669,2803,Inactive,124375976.0,367.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1032,743053,2,1,,144203669,2803,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1033,743054,2,1,,144203669,2803,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1034,743063,2,1,,144203669,2803,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1035,743064,3,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1036,743065,3,1,,144203669,2803,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1037,743066,3,1,,144203669,2803,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1038,743067,2,1,,144203669,2803,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1039,743069,2,1,,144203669,2803,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1040,743074,2,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1041,743075,2,1,,144203669,2803,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1042,743077,2,1,,144203669,2803,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1043,743078,2,1,,144203669,2803,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1044,743079,3,1,,144203669,2803,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1045,743080,3,1,,144203669,2803,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1046,743081,3,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1047,743083,3,1,,144203669,2803,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1048,743084,3,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1049,743085,3,1,,144203669,2803,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1050,743086,3,1,,144203669,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1051,743091,2,1,,144203669,2803,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1052,743094,3,1,,144203669,2803,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1053,743122,2,1,,144203669,2803,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1054,743139,2,1,,144203669,2803,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1055,743140,2,1,,144203669,2803,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1056,743191,3,1,,170464900,2803,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1057,743194,3,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1058,743199,2,1,,170464900,2803,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1059,743202,4,1,,170464900,2803,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1060,743203,3,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1061,743205,1,1,,90341662,2803,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1062,743205,1,1,,90341662,2803,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1063,743206,1,1,,90341662,2803,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1064,743206,1,1,,90341662,2803,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1065,743207,1,1,,90341662,2803,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1066,743207,1,1,,90341662,2803,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1067,743209,3,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1068,743210,4,1,,170464900,2803,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1069,743211,3,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1070,743212,3,1,,170464900,2803,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1071,743213,3,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1072,743215,3,1,,170464900,2803,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1073,743217,3,1,,170464900,2803,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1074,743218,3,1,,170464900,2803,Inconclusive,,,13.3322,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1075,743219,3,1,,170464900,2803,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1076,743220,3,1,,170464900,2803,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1077,743221,3,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1078,743222,3,1,,170464900,2803,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1079,743223,3,1,,170464900,2803,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1080,743224,3,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1081,743225,3,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1082,743226,2,1,,170464900,2803,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1083,743227,2,1,,170464900,2803,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1084,743228,3,1,,170464900,2803,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1085,743239,2,1,,170464900,2803,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1086,743240,2,1,,170464900,2803,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1087,743241,2,1,,170464900,2803,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1088,743242,2,1,,170464900,2803,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1089,743244,1,1,,90341662,2803,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1090,743244,1,1,,144203669,2803,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1091,743344,1,1,,104171138,2803,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
1092,743345,1,1,,104171138,2803,Inactive,,,0.0013,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
1093,743346,1,1,,104171138,2803,Inactive,,,13.3244,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
1094,743347,1,1,,104171138,2803,Inactive,,,0.1882,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
1095,764760,2,1,,103189246,2803,Unspecified,,,,,Permeability of the compound at 25 ug/ml after 18 hrs by PAMPA assay,Other,23870700.0,
1096,928639,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020513,Other,,
1097,928640,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020513,Other,,
1098,930655,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020513,Other,,
1099,930656,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020513,Other,,
1100,930657,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020513,Other,,
1101,930658,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020513,Other,,
1102,930659,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020513,Other,,
1103,930660,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020513,Other,,
1104,930661,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020513,Other,,
1105,930662,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020513,Other,,
1106,930663,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020513,Other,,
1107,930664,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020513,Other,,
1108,930665,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020513,Other,,
1109,930666,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020513,Other,,
1110,930667,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020513,Other,,
1111,930668,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020513,Other,,
1112,930669,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020513,Other,,
1113,930670,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020513",Other,,
1114,930671,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020513,Other,,
1115,931088,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020513,Other,,
1116,931089,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020513,Other,,
1117,931090,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020513,Other,,
1118,931091,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020513,Other,,
1119,931092,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020513,Other,,
1120,931093,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020513,Other,,
1121,931094,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020513,Other,,
1122,931095,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020513,Other,,
1123,931723,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020513,Other,,
1124,931724,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020513,Other,,
1125,931725,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020513",Other,,
1126,931726,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020513,Other,,
1127,931727,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020513,Other,,
1128,931728,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020513,Other,,
1129,931729,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020513,Other,,
1130,931730,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020513,Other,,
1131,931731,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020513,Other,,
1132,931732,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020513,Other,,
1133,931733,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020513,Other,,
1134,965019,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020513,Other,,
1135,965020,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020513,Other,,
1136,965021,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020513,Other,,
1137,965022,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020513,Other,,
1138,965023,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020513,Other,,
1139,965024,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020513,Other,,
1140,965025,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020513,Other,,
1141,965026,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020513,Other,,
1142,965027,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020513,Other,,
1143,965028,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020513,Other,,
1144,965428,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020513,Other,,
1145,965429,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020513,Other,,
1146,965430,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020513,Other,,
1147,965431,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020513,Other,,
1148,965432,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020513,Other,,
1149,965433,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020513,Other,,
1150,965434,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020513,Other,,
1151,965435,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020513,Other,,
1152,965436,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020513,Other,,
1153,971196,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020513,Other,,
1154,971197,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020513,Other,,
1155,971198,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020513,Other,,
1156,971199,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020513,Other,,
1157,971200,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020513,Other,,
1158,971201,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020513,Other,,
1159,971202,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020513,Other,,
1160,971203,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020513,Other,,
1161,971204,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020513,Other,,
1162,971205,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020513,Other,,
1163,971206,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020513,Other,,
1164,971207,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020513,Other,,
1165,971208,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020513,Other,,
1166,971209,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020513,Other,,
1167,971210,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020513,Other,,
1168,971211,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020513,Other,,
1169,971212,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020513,Other,,
1170,971843,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020513,Other,,
1171,971844,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020513,Other,,
1172,1016205,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1173,1016206,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020513",Other,,
1174,1016207,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020513",Other,,
1175,1016208,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020513",Other,,
1176,1016209,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020513",Other,,
1177,1016210,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020513",Other,,
1178,1016211,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020513",Other,,
1179,1016212,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020513",Other,,
1180,1016213,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020513",Other,,
1181,1016796,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020513",Other,,
1182,1016797,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020513",Other,,
1183,1016798,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020513",Other,,
1184,1016799,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020513",Other,,
1185,1016800,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020513",Other,,
1186,1016801,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020513,Other,,
1187,1016802,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020513",Other,,
1188,1016803,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020513",Other,,
1189,1016804,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020513",Other,,
1190,1016805,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1191,1016806,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1192,1016807,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020513",Other,,
1193,1016808,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020513",Other,,
1194,1016809,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020513,Other,,
1195,1016810,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020513",Other,,
1196,1016811,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020513",Other,,
1197,1016812,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020513",Other,,
1198,1016813,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020513",Other,,
1199,1016814,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020513",Other,,
1200,1016815,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020513",Other,,
1201,1016816,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1202,1018642,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020513",Other,,
1203,1018643,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020513",Other,,
1204,1018644,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1205,1018645,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020513",Other,,
1206,1018646,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020513",Other,,
1207,1018647,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1208,1018648,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020513",Other,,
1209,1018649,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1210,1018650,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020513",Other,,
1211,1018651,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020513",Other,,
1212,1018652,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020513",Other,,
1213,1018653,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020513",Other,,
1214,1018654,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020513",Other,,
1215,1018655,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020513",Other,,
1216,1018656,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020513",Other,,
1217,1018657,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020513",Other,,
1218,1018658,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020513",Other,,
1219,1018659,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020513",Other,,
1220,1018660,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020513",Other,,
1221,1018661,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020513",Other,,
1222,1018662,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020513",Other,,
1223,1019247,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020513",Other,,
1224,1019248,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020513,Other,,
1225,1019249,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020513,Other,,
1226,1019250,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020513",Other,,
1227,1019251,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020513",Other,,
1228,1019252,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020513",Other,,
1229,1019253,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020513",Other,,
1230,1019254,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1231,1019255,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020513",Other,,
1232,1019256,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020513",Other,,
1233,1019257,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020513",Other,,
1234,1019258,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020513",Other,,
1235,1019259,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020513",Other,,
1236,1019260,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020513,Other,,
1237,1019261,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1238,1019262,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020513",Other,,
1239,1019263,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020513",Other,,
1240,1019264,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020513",Other,,
1241,1019265,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020513,Other,,
1242,1021097,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020513",Other,,
1243,1021098,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020513",Other,,
1244,1021099,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020513",Other,,
1245,1021100,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020513",Other,,
1246,1021101,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020513",Other,,
1247,1021102,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020513",Other,,
1248,1021103,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020513",Other,,
1249,1021104,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020513",Other,,
1250,1021105,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020513",Other,,
1251,1021106,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020513",Other,,
1252,1021107,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020513,Other,,
1253,1021108,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020513",Other,,
1254,1021109,1,3,,103189246,2803,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020513,Other,,
1255,1021110,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020513",Other,,
1256,1021111,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020513",Other,,
1257,1021695,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020513",Other,,
1258,1021696,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020513",Other,,
1259,1021697,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020513",Other,,
1260,1021698,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020513",Other,,
1261,1021699,1,3,,103189246,2803,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020513",Other,,
1262,1056992,1,1,,103189246,2803,Unspecified,,,,,Permeability of the compound by PAMPA,Other,24128814.0,
1263,1056993,1,1,,103189246,2803,Unspecified,,,,,Permeability of the compound at 100 mg/mL after 10 hrs by PAMPA,Other,24128814.0,
1264,1071344,1,1,,103189246,2803,Unspecified,,,,,Permeability of the compound by BBB-PAMPA,Other,24389509.0,
1265,1079931,1,1,,103189246,2803,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1266,1079932,1,1,,103189246,2803,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1267,1079933,1,1,,103189246,2803,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1268,1079934,1,1,,103189246,2803,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1269,1079935,1,1,,103189246,2803,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1270,1079936,1,1,,103189246,2803,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1271,1079937,1,1,,103189246,2803,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1272,1079938,1,1,,103189246,2803,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1273,1079939,1,1,,103189246,2803,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1274,1079940,1,1,,103189246,2803,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1275,1079941,1,1,,103189246,2803,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1276,1079942,1,1,,103189246,2803,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1277,1079943,1,1,,103189246,2803,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1278,1079944,1,1,,103189246,2803,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1279,1079945,1,1,,103189246,2803,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1280,1079946,1,1,,103189246,2803,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1281,1079947,1,1,,103189246,2803,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1282,1079948,1,1,,103189246,2803,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1283,1079949,1,1,,103189246,2803,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1284,1091955,1,2,,103189246,2803,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
1285,1091956,1,1,,103189246,2803,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
1286,1091957,1,1,,103189246,2803,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
1287,1091958,2,1,,103189246,2803,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
1288,1093190,1,2,,103189246,2803,Active,,,0.95499,Ki,Binding affinity to I2 imidazoline binding site (unknown origin),Confirmatory,,
1289,1093191,2,3,,103189246,2803,Active,205829312.0,306255.0,0.1122,Ki,Binding affinity to I1 imidazoline binding site in Rattus norvegicus (rat) PC12 cells,Confirmatory,,
1290,1097336,1,3,,103189246,2803,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
1291,1117298,1,2,,170464900,2803,Inactive,,,0.631,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
1292,1117304,1,2,,170464900,2803,Inactive,,,5.0119,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
1293,1117305,1,2,,170464900,2803,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
1294,1117310,1,1,,170464900,2803,Inactive,,,0.630957,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
1295,1117312,1,1,,170464900,2803,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
1296,1117314,1,1,,170464900,2803,Inactive,,,5.01187,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
1297,1117326,1,1,,170464900,2803,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
1298,1117329,1,1,,170464900,2803,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
1299,1117336,1,1,,170464900,2803,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
1300,1117340,1,1,,170464900,2803,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
1301,1117341,1,1,,170464900,2803,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
1302,1117342,1,1,,170464900,2803,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
1303,1117343,1,1,,170464900,2803,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
1304,1117346,1,1,,170464900,2803,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
1305,1139646,1,1,,103189246,2803,Unspecified,,,,,Permeability of the compound at 5 mg/mL after 18 hrs by PAMPA,Other,24697335.0,
1306,1150071,1,2,,103189246,2803,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive rat assessed as reduction in mean arterial blood pressure at 0.5 mg/kg, po administered as two dose at 24 hrs interval measured 4 hrs post second dose relative to control",Other,915918.0,
1307,1150955,1,1,,103189246,2803,Unspecified,,,,,"Retardation factor, deltaRm of the compound at pH 13 by TLC analysis",Other,9510.0,
1308,1150956,2,1,,103189246,2803,Unspecified,,,,,"Octan-1-ol-aqueous buffer partition coefficient, log P of the compound at 10 to 20 mg at pH 7.4 by UV-spectroscopic analysis",Other,9510.0,
1309,1150957,1,1,,103189246,2803,Unspecified,,,,,"Dissociation constant, pKa of the compound in water-ethyl alcohol",Other,9510.0,
1310,1150958,1,2,,103189246,2803,Unspecified,,,,,Hypotensive activity in rat assessed as change in mean blood pressure relative to control,Other,9510.0,
1311,1150959,1,2,,103189246,2803,Unspecified,,,,,Peripheral adrenergic activity in iv dosed pithed rat assessed as change in mean blood pressure,Other,9510.0,
1312,1159509,1,1,,170464900,2803,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1313,1159515,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1314,1159516,1,1,,170464900,2803,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1315,1159517,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1316,1159518,1,1,,170464900,2803,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1317,1159519,1,1,,170464900,2803,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1318,1159520,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1319,1159521,1,1,,170464900,2803,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1320,1159523,1,1,,170464900,2803,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1321,1159524,1,1,,124879741,2803,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1322,1159524,1,1,,124879743,2803,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1323,1159525,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1324,1159526,1,1,,170464900,2803,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1325,1159527,1,1,,170464900,2803,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1326,1159528,1,1,,170464900,2803,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1327,1159529,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1328,1159531,1,1,,170464900,2803,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1329,1159551,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1330,1159552,1,1,,170464900,2803,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1331,1159553,2,1,,170464900,2803,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1332,1159555,1,1,,170464900,2803,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1333,1159580,2,1,,268735299,2803,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1334,1159580,2,1,,273002755,2803,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1335,1159607,2,1,,312309676,2803,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1336,1159614,1,2,,170464900,2803,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
1337,1159620,1,1,,103189246,2803,Active,,,,,Summary of drug indications.,Other,,
1338,1161578,1,1,,103189246,2803,Unspecified,,,,,Permeability of the compound by PAMPA-BBB assay,Other,25156301.0,
1339,1167550,1,1,,103189246,2803,Unspecified,,,,,Permeability of the compound in 70:30 PBS:EtOH by PAMPA-BBB assay,Other,25282266.0,
1340,1167634,1,1,,103189246,2803,Unspecified,,,,,Blood brain permeability of the compound at donor and acceptor by PAMPA assay,Other,25282654.0,
1341,1173449,1,1,,103189246,2803,Unspecified,,,,,Effective permeability of the compound by PAMPA assay,Other,25454267.0,
1342,1183278,1,1,,103189246,2803,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25016233.0,
1343,1192730,1,1,,103189246,2803,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25614117.0,
1344,1192731,1,1,,103189246,2803,Unspecified,,,,,Permeability of the compound in PBS/EtOH buffer at 100 ug/ml by PAMPA,Other,25614117.0,
1345,1194507,1,1,,103189246,2803,Active,,,0.00251,Ki,Displacement of [3H]clonidine from rat cerebral cortex alpha-2 adrenergic receptor by liquid scintillation counting analysis,Confirmatory,25813897.0,
1346,1195978,1,2,,103189246,2803,Active,205829312.0,306255.0,0.0141,Ki,Displacement of [125I] PIC from I1 imidazoline receptor in rat PC12 cells after 45 mins by gamma counting,Confirmatory,25521963.0,
1347,1195979,1,2,,103189246,2803,Active,1351829.0,150.0,0.0038,Ki,Displacement of [3H]RX821002 from human alpha2 adrenoceptor expressed in CHO cell membranes after 60 mins,Confirmatory,25521963.0,
1348,1195979,1,2,,103189246,2803,Active,20141211.0,152.0,0.0038,Ki,Displacement of [3H]RX821002 from human alpha2 adrenoceptor expressed in CHO cell membranes after 60 mins,Confirmatory,25521963.0,
1349,1195979,1,2,,103189246,2803,Active,613504690.0,151.0,0.0038,Ki,Displacement of [3H]RX821002 from human alpha2 adrenoceptor expressed in CHO cell membranes after 60 mins,Confirmatory,25521963.0,
1350,1195980,1,1,,103189246,2803,Unspecified,,,,,Selectivity ratio of Ki for I1 imidazoline receptor in rat PC12 cells to Ki for human alpha2 adrenoceptor expressed in CHO cell membranes,Other,25521963.0,
1351,1198140,1,1,,103189246,2803,Unspecified,,,,,Permeability of the compound in PBS and EtOH by PAMPA method,Other,25656088.0,
1352,1201746,1,1,,103189246,2803,Unspecified,,,,,Permeability of the compound after 16 hrs by PAMPA,Other,25812965.0,
1353,1201747,1,1,,103189246,2803,Unspecified,,,,,Permeability of the compound by PAMPA,Other,25812965.0,
1354,1209581,1,2,,103189246,2803,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
1355,1209582,1,1,,103189246,2803,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
1356,1209583,1,1,,103189246,2803,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
1357,1209593,1,1,,103189246,2803,Unspecified,,,,,"Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
1358,1224824,1,1,,104171138,2803,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
1359,1224825,1,1,,104171138,2803,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
1360,1224834,3,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1361,1224835,1,1,,170464900,2803,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1362,1224836,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1363,1224837,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1364,1224838,1,1,,170464900,2803,Inconclusive,66775687.0,9970.0,2.9849,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1365,1224839,1,1,,170464900,2803,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1366,1224840,3,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1367,1224841,3,1,,170464900,2803,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1368,1224842,3,1,,170464900,2803,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1369,1224843,1,1,,170464900,2803,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1370,1224844,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1371,1224845,1,1,,170464900,2803,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1372,1224846,1,1,,170464900,2803,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1373,1224847,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1374,1224848,3,1,,170464900,2803,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1375,1224849,3,1,,170464900,2803,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1376,1224857,2,1,,104171138,2803,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1377,1224857,2,1,,170464900,2803,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1378,1224859,2,1,,90341662,2803,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1379,1224859,2,1,,104171138,2803,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1380,1224859,2,1,,170464900,2803,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1381,1224863,1,1,,176483964,2803,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1382,1224863,1,1,,176484874,2803,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1383,1224863,1,1,,316919421,2803,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1384,1224867,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1385,1224868,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1386,1224869,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1387,1224870,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1388,1224871,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1389,1224872,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1390,1224873,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1391,1224874,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1392,1224875,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1393,1224876,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1394,1224877,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1395,1224878,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1396,1224879,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1397,1224880,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1398,1224881,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1399,1224882,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1400,1224883,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1401,1224884,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1402,1224885,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1403,1224886,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1404,1224887,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1405,1224888,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1406,1224889,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1407,1224890,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1408,1224892,1,1,,170464900,2803,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1409,1224893,1,1,,170464900,2803,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1410,1224894,1,1,,170464900,2803,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1411,1224895,1,1,,170464900,2803,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1412,1224896,1,1,,170464900,2803,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1413,1224905,2,1,,92308807,2803,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1414,1224905,2,1,,92308807,2803,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1415,1259241,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1416,1259242,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1417,1259243,1,1,,170464900,2803,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1418,1259244,1,1,,170464900,2803,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1419,1259247,1,1,,170464900,2803,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1420,1259248,1,1,,170464900,2803,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1421,1259252,1,1,,104171138,2803,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
1422,1259253,1,1,,104171138,2803,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
1423,1259255,1,1,,104171138,2803,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
1424,1259256,1,1,,104171138,2803,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
1425,1259310,1,1,,333473307,2803,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1426,1259325,1,2,,336954533,2803,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
1427,1259344,1,1,,144203669,2803,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1428,1259354,1,1,,348452275,2803,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
1429,1259355,1,1,,26751841,2803,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1430,1259356,1,1,,104171138,2803,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1431,1259364,1,1,,170464900,2803,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1432,1259365,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1433,1259366,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1434,1259367,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1435,1259368,1,1,,170464900,2803,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1436,1259369,1,1,,170464900,2803,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1437,1259377,1,1,,170464900,2803,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1438,1259378,1,1,,170464900,2803,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1439,1259379,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1440,1259380,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1441,1259381,1,1,,170464900,2803,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1442,1259382,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1443,1259383,1,1,,170464900,2803,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1444,1259384,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1445,1259385,1,1,,170464900,2803,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1446,1259386,1,1,,170464900,2803,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1447,1259387,1,1,,170464900,2803,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1448,1259388,1,1,,170464900,2803,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1449,1259390,1,1,,170464900,2803,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1450,1259391,1,1,,170464900,2803,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1451,1259392,1,1,,170464900,2803,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1452,1259393,1,1,,170464900,2803,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1453,1259394,1,1,,170464900,2803,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1454,1259395,1,1,,170464900,2803,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1455,1259396,1,1,,170464900,2803,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1456,1259400,1,1,,170464900,2803,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1457,1259401,1,1,,170464900,2803,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1458,1259402,1,1,,170464900,2803,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1459,1259403,1,1,,170464900,2803,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1460,1259404,1,1,,170464900,2803,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1461,1259407,1,1,,363905737,2803,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1462,1259416,1,2,,340079750,2803,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1463,1259416,1,2,,375174940,2803,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1464,1259421,1,1,,340079750,2803,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1465,1259421,1,1,,375174940,2803,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1466,1259423,1,2,,354785186,2803,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1467,1259423,1,2,,354798581,2803,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1468,1259423,1,2,,354947193,2803,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1469,1259423,1,2,,355008020,2803,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
